Document:

EX-4.16

Table of Contents

 Exhibit 4.16 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such
excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
 Tech Transfer
and Manufacturing Services Agreement 
 (the “Agreement”) 

by and between 
 Lonza Ltd 

Münchensteinerstrasse 38 

CH-4002 Basel 

Switzerland 
 - hereinafter
“Lonza” - 
 and 
 Ascendis Pharma A/S 

Company Reg. No. 29918791 
 Tuborg Boulevard 12

 2900 Hellerup 
 Denmark 

- hereinafter “Customer” - 

Effective as of December 12, 2019 (the “Effective Date”) 

Table of Contents

 Table of Contents 

 

							
	 	  	 	  	Page	 
			
	1	  	Definitions and Interpretation	  	 	1	 
			
	2	  	Performance of Services	  	 	8	 
			
	3	  	Project Management / Steering Committee	  	 	10	 
			
	4	  	Quality	  	 	10	 
			
	5	  	Insurance	  	 	11	 
			
	6	  	Forecasting, Ordering and Cancellation	  	 	11	 
			
	7	  	Delivery and Acceptance	  	 	13	 
			
	8	  	Price and Payment	  	 	15	 
			
	9	  	Capital Equipment	  	 	16	 
			
	10	  	Intellectual Property	  	 	16	 
			
	11	  	Warranties	  	 	18	 
			
	12	  	Indemnification and Liability	  	 	19	 
			
	13	  	Confidentiality	  	 	20	 
			
	14	  	Compliance	  	 	22	 
			
	15	  	Term and Termination	  	 	22	 
			
	16	  	Force Majeure	  	 	24	 
			
	17	  	Miscellaneous	  	 	24	 
		
	 Appendix A
	  			
		
	 Appendix B
	  			
		
	 Appendix C
	  			
		
	 Appendix D
	  			
		
	 Appendix E
	  			
		
	 Appendix F
	  			
		
	 Appendix G
	  			
		
	 Appendix H
	  			

Table of Contents

 Recitals 

WHEREAS, Customer is engaged in the development, research and commercialization of certain products and requires assistance in the development and manufacture
of such product(s); 
 WHEREAS, Lonza and its Affiliates have expertise in the evaluation, development and manufacture of products; 

WHEREAS, Customer wishes to engage Lonza for Services relating to the development and manufacture of the Product as described in this Agreement; and 

WHEREAS, Lonza, or its Affiliate, is prepared to perform such Services for Customer on the terms and subject to the conditions set out herein. 

NOW, THEREFORE, in consideration of the mutual promises contained herein, and for other good and valuable consideration, the parties intending to be legally
bound, agree as follows: 
  

	1	 Definitions and Interpretation 

 

			
	“Affiliate”	  	means any company, partnership or other entity which directly or indirectly Controls, is Controlled by or is under common Control with the relevant Party. “Control” means the ownership of more than fifty percent (50%) of
the issued share capital or the legal power to direct or cause the direction of the general management and policies of the relevant Party.
		
	“Agreement”	  	means this agreement incorporating all Appendices, as amended from time to time by written agreement of the Parties.
		
	“Applicable Laws”	  	means all relevant [***] federal, state and local laws, statutes, rules, and regulations which are applicable to the performance of the Services (as defined below) and/or the Parties’ respective obligations hereunder,
including, without limitation, the applicable regulations and guidelines of any Governmental Authority and all applicable cGMP together with amendments thereto and shall be expanded to [***], at Ascendis’ sole discretion and according to
timelines subject to both Parties’ mutual agreement reached in good faith; the Parties will cooperate in good faith in order to allow for an expansion to any further jurisdiction, including but not limited to [***] it being understood that any
such expansion shall be subject to mutual agreement between the Parties.
		
	“Approval”	  	means the first marketing approval by the FDA or EMA or other Regulatory Authority of the Drug Product manufactured by using the Product from the Facility for commercial supply.

  
 1 

Table of Contents

			
	“Background Intellectual Property”	  	means any Intellectual Property either (i) owned or controlled by a Party prior to the Effective Date or (ii) developed or acquired by a Party independently from the performance of the Services hereunder during the Term of
this Agreement.
		
	“Batch”	  	means the Product derived from a single run of the Manufacturing Process.
		
	“Batch Price”	  	means the Price of each Batch.
		
	“Batch Record”	  	means the executed document on the basis of the respective Master Batch Record containing the production record, or, as applicable, relevant portions thereof, pertaining to a given Batch, including the documentation on paper or in
electronic form as EBR electronic batch record, created as and after each Batch is processed that, when complete and accurate, reflects and incorporates all aspects with respect to such Batch.
		
	“Campaign”	  	means a series of no less than [***] ([***]) cGMP Batches manufactured consecutively.
		
	“Cancellation Fee”	  	has the meaning given in Clause 6.7.
		
	 “[***]”
	  	 shall  have the meaning set out in Clause 9.1.

		
	“Capital Equipment”	  	means those certain pieces of equipment described in the Project Plan used to produce the Product that are purchased by Customer or for which Customer reimburses Lonza, including, without limitation, the related documentation
regarding the design, validation, operation, calibration and maintenance of such equipment. For the avoidance of doubt, Capital Equipment does not include equipment already owned by Lonza as per the Effective Date, nor does it include replacement of
such equipment [***].
		
	“Certificate of Analysis” or “CoA”	  	means a document prepared by Lonza listing tests performed by Lonza or approved External Laboratories, on representative Batch sample(s), setting forth the Specifications, test methods used, actual results, date and signature of
authorised personnel, and other technical information deemed necessary for its proper use, and, if External Laboratories have performed any such tests, the name and address of such External Laboratories.
		
	“Certificate of Compliance” or “CoC”	  	means a document prepared by Lonza: (i) listing the manufacturing date, unique Batch number,

  
 2 

Table of Contents

			
		  	and concentration of Product in such Batch, (ii) certifying that such Batch was manufactured in accordance with the Master Batch Record and cGMP, if applicable.
		
	“cGMP”	  	means those laws and regulations applicable in [***], relating to the manufacture of medicinal products for human use, including, without limitation, current good manufacturing practices as specified in the ICH guidelines, including
without limitation, ICH Q7A “ICH Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients”, US Federal Food Drug and Cosmetic Act at 21CFR (Chapters 210, 211, 600 and 610, 820) and the Guide to Good Manufacturing Practices
for Medicinal Products as promulgated under European Directive 91/356/EEC. For the avoidance of doubt, Lonza’s operational quality standards are defined in internal cGMP policy documents.
		
	 “cGMPBatches”
	  	means any Batches which are required under the Project Plan to be manufactured in accordance with cGMP.
		
	“Change”	  	means any change to the Services, pricing or Scope of Work incorporated into a written amendment to the Agreement in accordance with clause 17.2 or effected in accordance with the Quality Agreement.
		
	“Commencement Date”	  	means the date of commencement of manufacturing activities for a Batch hereunder.
		
	“Confidential Information”	  	means Customer Information and Lonza Information, as the context requires.
		
	“Customer Information”	  	means all technical and other information that is proprietary to Customer and that is maintained in confidence by Customer and that is disclosed by Customer to Lonza or in the public domain relating to the Manufacturing Process and
the Product, from time to time supplied by the Customer to Lonza, including any materials supplied by Customer to Lonza in accordance with the Project Plan.
		
	“Customer Materials”	  	means any Raw Materials, components of Product, or other materials of any nature provided by Customer as agreed between the Parties, including, without limitation, any handling instructions, protocols, SOPs and other documentation
necessary to maintain the properties of such Customer Materials for the performance of the Project Plan.

  
 3 

Table of Contents

			
	“Customer Release”	  	has the meaning given in Clause 7.1.
		
	“[***] Date”	  	means the date Customer Release is given regarding a Batch or [***] days after Lonza Release, whichever comes first.
		
	“Development Services”	  	means all Services other than Manufacturing Services.
		
	“Drug Product”	  	means any drug product incorporating Product.
		
	“EMA”	  	means the European Medicines Agency, or any successor agency thereto.
		
	“Engineering Batches”	  	means a Batch that is intended to demonstrate the transfer of the Manufacturing Process to the Facility.
		
	“External Laboratories”	  	means any Third Party instructed by Lonza, with Customer’s prior consent, which is to conduct laboratory services activities required to complete the Services which are not customarily offered by Lonza and performed on an
independent and impartial basis.
		
	“Facility”	  	means, for the manufacture of Product, [***], or, to the extent agreed between Customer and Lonza, for the manufacture of [***], [***], or such other Lonza facility as may be agreed upon by the Parties.
		
	“FDA”	  	means the United States Food and Drug Administration, or any successor agency thereto.
		
	Flex Batch”	  	has the meaning given in Clause 6.1.2(a).
		
	“GDPR”	  	means the European Union General Data Privacy Regulation.
		
	“Governmental Authority”	  	means any Regulatory Authority and any national, multi-national, regional, state or local regulatory agency, department, bureau, or other governmental entity in [***] or such other jurisdiction as the Parties may mutually agree upon
in alignment with any expansion of the Applicable Law.
		
	“International Trade Restrictions”	  	means all applicable [***] export control, trade, and financial sanctions laws, rules, and regulations.
		
	“Intellectual Property”	  	means (i) inventions (whether or not patentable), patents, trade secrets, copyrights, trademarks, trade names and domain names, rights in designs, rights in computer software, database

  
 4 

Table of Contents

			
		  	rights, rights in confidential information (including know-how) and any other intellectual property rights, in each case whether registered or unregistered, (ii) all applications (or
rights to apply) for, and renewals or extensions of, any of the rights described in the foregoing clause (i) and (iii) all rights and applications that are similar or equivalent to the rights and application described in the foregoing clauses
(i) and (ii), which exist now, or which come to exist in the future, in any part of the world.
		
	“Lonza Information”	  	means all information that is proprietary to Lonza or any Affiliate of Lonza and that is maintained in confidence by Lonza or any Affiliate of Lonza and that is disclosed by Lonza or any Affiliate of Lonza to Customer under or in
connection with this Agreement, including without limitation, any and all Lonza know-how and trade secrets.
		
	“Lonza Operating Documents”	  	means the corporate standards, standard operating procedures, standard manufacturing procedures, Lonza-customized manufacturing procedures developed or outside the scope of this Agreement, electronic programs and files, raw material
specifications, protocols, validation documentation, and supporting documentation used by Lonza, without limitation, [***], excluding any of the foregoing that are unique to the manufacture of Product.
		
	“Lonza Release”	  	has the meaning given in Clause 7.1.
		
	“Manufacturing Process”	  	means the production process provided by Customer to Lonza for the manufacture of Product, as such process may be improved or modified from time to time by agreement of the Parties in writing.
		
	“Manufacturing Services”	  	means the services related to the manufacturing of Batches (including Engineering Batches and PPQ Batches), as well as the related pre-production activities and, to the extent agreed by the Parties in an amendment hereto, the
manufacturing of related materials, such as any enzymes to be used for the manufacturing of the Product (including [***]); for the avoidance of any doubt, the manufacturing of any Engineering Batch or Process Validation Batch or commercial Batch is
deemed Manufacturing Services.
		
	“Master Batch Record”	  	means the formal set of unexecuted master production and control records and instructions for the manufacture of the Product or, to the extent requested by Customer, the [***] that

  
 5 

Table of Contents

			
		  	details steps and elements of the Manufacturing Process, along with analytical methods, test methods and other procedures, directions and controls associated with the manufacture and testing of the Product.
		
	“Modified Manufacturing Process”	  	means a Manufacturing Process that has been improved or modified by agreement of the Parties and incorporates any Lonza Information, Lonza Background Intellectual Property and/or New General Application Intellectual
Property.
		
	“New Customer Intellectual Property”	  	has the meaning given in Clause 10.2.
		
	“New General Application Intellectual Property”	  	has the meaning given in Clause 10.3.
		
	“Party”	  	means each of Lonza and Customer and, together, the “Parties”.
		
	“Price”	  	means the price for the Services and Products as set out in Appendix A.
		
	“Process Validation Batch or PPQ Batch”	  	means a Batch that is produced in compliance with cGMP with the intent to show reproducibility of the Manufacturing Process and is required to complete process validation studies.
		
	“Product”	  	means the proprietary molecule identified by Customer as TransCon [***] human Growth Hormone (TC hGH) [***] to be manufactured using the Manufacturing Process by Lonza for Customer as specified in the Project Plan.
		
	“Project Plan”	  	means the plan(s) describing the Services to be performed by Lonza under this Agreement, including any update and amendment of the Project Plan to which the Parties may agree from time to time. The initial Project Plan is attached
hereto as Appendix A.
		
	“Purchase Order”	  	shall have the meaning ascribed in Clause 6.2.
		
	“Roadmap”	  	shall have the meaning ascribed in Clause 2.2.1.
		
	“Quality Agreement”	  	means the quality agreement, attached or to be attached no later than before commencement of any cGMP manufacturing hereto as Appendix H, that delineates, defines, establishes, and documents manufacturing and testing activities and
responsibilities of the Parties subject to cGMP requirements.

  
 6 

Table of Contents

			
	“Raw Materials”	  	means all ingredients, including [***] unless such [***] is manufactured by Lonza based on an amendment to this Agreement between the Parties, and [***] required to perform the Manufacturing Process or Services set forth in the bill
of materials detailing the same (including any consumables or wearables).
		
	“Raw Materials Handling Fee”	  	means the procurement and handling fee of a percentage, as stipulated in Clause 8.2, of the acquisition cost of Raw Materials other than Customer Materials by Lonza that is charged to the Customer in addition to the cost of such Raw
Materials. For the avoidance of doubt: If Lonza manufactures [***] for Customer, such shall be priced according to an agreed batch fee and shall not be subject to the Raw Materials Handling Fee, except for the Raw Materials used in such enzyme
production.
		
	“Recall”	  	has the meaning given in Clause 12.4
		
	“Regulatory Authority”	  	means the [***] and any other similar regulatory authorities as may be agreed upon in writing by the Parties that are responsible for administering and/or granting approvals for the performance of Services under this Agreement or
for issuing regulations pertaining to the manufacture and/or use of Product in [***] or in such other countries as the Parties may mutually agree upon.
		
	“[***]”	  	means [***], as specified in the Master Batch Record.
		
	“[***] Handling Fee”	  	means the procurement and handling fee of a percentage, as stipulated in Clause 8.2, of the acquisition cost of [***] by Lonza that is charged to the Customer in addition to the cost of such [***].
		
	“Services”	  	means all or any part of the services to be performed by Lonza or its Affiliates under this Agreement (including, without limitation, process and analytical method transfer, process development, process optimization, validation, BLA
related activities, clinical and commercial Manufacturing Services, as well as quality control and quality assurance activities including without limitation analytical activities), particulars of which are set out in a Project Plan.
		
	“SOP”	  	means a standard operating procedure.
		
	“Specifications”	  	means the specifications of the Product as specified in Appendix B, which may be amended from time to time by mutual consent of both Parties in accordance with this Agreement.

  
 7 

Table of Contents

			
	“Subcontractors”	  	means any Third Party, which is not an External Laboratory, instructed by Lonza, with Customer’s prior consent, which is to conduct activities required to complete the Services.
		
	“[***]”	  	means [***].
		
	“Term”	  	has the meaning given in Clause 15.1.
		
	“Third Party”	  	means any party other than Customer, Lonza and their respective Affiliates.

 In this Agreement references to the Parties are to the Parties to this Agreement, headings are used for convenience only and
do not affect its interpretation, references to a statutory provision include references to the statutory provision as modified or re-enacted or both from time to time and to any subordinate legislation made
under the statutory provision, references to the singular include the plural and vice versa, and references to the word “including” are to be construed without limitation. 

 

	2	 Performance of Services 

 

	2.1	 Performance of Services. Subject to Clause 2.3, Lonza shall itself and/or through its Affiliates,
diligently carry out the Services as provided in the Project Plan and [***] perform the Services without defect and according to the estimated timelines as set forth in the Project Plan. Lonza shall retain appropriately qualified and trained
personnel with the requisite knowledge and experience to perform the Services in accordance with current industry standards and the terms of this Agreement. Lonza may subject to Customer’s prior written approval subcontract or delegate parts of
its performance of the Services to Subcontractors or External Laboratories, it being understood that Lonza will clarify at the time of seeking approval, whether the engagement is for a Subcontractor or External Laboratory; provided, that any
Subcontractors shall be subject to the same obligations and other provisions contained in this Agreement or any applicable Project Plan. [***]. 

  

	2.2	 Technology Transfer to Lonza. 

 

	 	2.2.1	 The Parties expressly agree that they shall work together to transfer the Manufacturing Process to the
Facility, including implementing the technology transfer plan set forth in the Project Plan. Customer shall [***] support such technology transfer as reasonably requested by Lonza. A roadmap has been compiled and agreed by the Parties towards [***]
(the “Roadmap”). Upon alignment between Customer and Lonza on the Roadmap, activities for the technology transfer will be started. 

  

	 	2.2.2	 Based on the information provided by Customer and including process changes developed by Lonza pursuant to any
applicable Project Plan, Customer shall inform Lonza of any specific requirements Customer may have, including, without limitation, any information or procedures Customer wishes to have incorporated therein. [***]. 

 

	2.3	 Engineering Batches. Lonza shall manufacture Engineering Batches in accordance with the Project Plan.
Customer shall have the right to make whatever further use of 

  
 8 

Table of Contents

	 	
the non-cGMP Engineering Batches as it shall determine, provided that Customer pays for such Batches, such use is not for human use and does not violate
any Applicable Laws. Lonza makes no warranty that Engineering Batches will meet cGMP or the Specifications. [***] Regardless of whether any Engineering Batch meets cGMP or the Specifications, Customer shall pay to Lonza the Price for such
Engineering Batch plus the Raw Materials Handling Fee associated with such Engineering Batches. 

  

	2.4	 cGMP Batches. Lonza will, in accordance with the terms of this Agreement and Quality Agreement,
manufacture at the Facility and release to Customer, cGMP Batches that comply with the Manufacturing Process, cGMP and the Specifications, together with a Certificate of Analysis; [***]. Prior to commencement of cGMP manufacturing, Lonza shall
review the process assumptions. In the event that there is a material difference in the process assumptions as compared with the process results demonstrated during the manufacture of Engineering Batches, [***]. 

 

	2.5	 Process Validation Batches. Lonza shall manufacture and deliver Process Validation Batches as mutually
agreed by Parties sufficient to document the operability and reproducibility of the Manufacturing Process and permit the Parties to complete and file the necessary regulatory documents. 

 

	 	2.5.1	 Prior to commencement of Process Validation Batches, Lonza and Customer shall agree a process validation plan
identifying the validation requirements of the Manufacturing Process. All process validation activities are excluded from the Price of Process Validation Batches and shall be approved separately by the Customer in advance and shall be paid for by
the Customer at the Price set out in the applicable Project Plan. 

  

	 	2.5.2	 Any regulatory support activities (including pre-Approval inspection)
required and agreed to by Customer to support the Approval of the Product from the Facility shall be performed and supported by Lonza as reasonably requested by Customer or required by a Governmental Authority[***]. All such regulatory support
activities are excluded from the Price of Process Validation Batches, and shall be approved by the Customer in advance, and shall be paid for by the Customer at the Price set out in the applicable Project Plan (and/or amendments to this Agreement or
scope change documents). 

  

	2.6	 Supply of Customer Information and Customer Materials. Customer shall supply to Lonza all Customer
Information and Customer Materials and other information or materials that may be reasonably required by Lonza to perform the Services. [***]. Customer Materials shall remain the property of the Customer and shall until processing be clearly marked
as such [***]. 

  

	2.7	 Raw Materials. Lonza shall procure all required Raw Materials as well as consumables other than those
Raw Materials that are Customer Materials. At Customer’s sole discretion and upon advance payment by Customer, Lonza shall purchase and hold a minimum of [***] ([***]) (or such other number the Parties may mutually agree upon at a later stage)
extra Batch’s requirements of Raw Materials to serve as safety stock. Customer shall be responsible for payment for all consumables and Raw Materials ordered or irrevocably committed to be procured by Lonza hereunder. The Parties recognize and
agree that any Raw Materials or [***] fully paid up in advance by the Customer is the property of the Customer. Upon cancellation of any Batch or termination of the Agreement, all unused Raw Materials which cannot be used by Lonza for the
manufacture of other products for other customers shall be paid for by Customer within [***] ([***]) days of invoice and at Customer’s option and cost will either be (a) held by Lonza for future use for the production of Product for up to
[***] of the last Process Validation Batch and (b) [***] ([***]) months thereafter, (b) delivered to Customer, or (c) disposed of [***]. 

  
 9 

Table of Contents

	3	 Project Management / Steering Committee 

 

	3.1	 Project Plans. With respect to a new project to be governed by this Agreement, a new Project Plan shall
be added by agreement in writing signed by the Parties and appended to Appendix A. Each Project Plan shall include a description of the Services to be provided, the Product to be manufactured, Specifications, a schedule for completion of the Project
Plan, pricing details, and such other information as is necessary for relevant Services. In the event of a conflict between the terms of a Project Plan and this Agreement, the terms of this Agreement will govern. 

 

	3.2	 Project Management. With respect to each Project Plan, each party will appoint a project manager who
will be the party responsible for overseeing the Project Plan. 

  

	3.3	 Steering Committee. Each Party shall name a mutually agreed upon equal number of representatives for the
Steering Committee, which shall meet [***] per calendar year, or as otherwise mutually agreed by the Parties. In the event that a Steering Committee dispute cannot be resolved, such dispute shall be escalated to a senior executive of each of
Customer and Lonza. 

 The primary function of the Steering Committee is to ensure the ongoing communication between the
Parties and discuss and resolve any issues arising under this Agreement. In addition to the primary function described above, the Steering Committee shall also take on the following responsibilities: 

 

	 	3.3.1	 discuss and seek resolution of issues around management of the Services; 

 

	 	3.3.2	 agree and monitor deadlines and milestones for the Services; and 

 

	 	3.3.3	 discuss and recommend any changes to the Services (although such changes will not take effect until they have
been incorporated into a written amendment to the Project Plan which has been signed by the Parties). 

  

	3.4	 Person in Plant. Customer shall be permitted to have, at no additional cost, [***] ([***]) [***] at the
Facility as reasonably requested by Customer, at any time during the Manufacturing Process and related analytical services for the purpose of observing, reporting on, and consulting as to the performance of the Services. Such employee shall be
subject to and agree to abide by confidentiality obligations to Third Parties and Lonza’s customary practices and operating procedures regarding persons in plant, and such employee agrees to comply with all instructions of Lonza’s
employees at the Facility. Furthermore, Lonza shall use commercially reasonable endeavours that Customer is allowed similar access to key Subcontractors and External Laboratories. 

 

	4	 Quality 

  

	4.1	 Responsibility for quality assurance and quality control of Product shall be allocated between Customer and
Lonza as set forth in the Quality Agreement and in Lonza standard operating procedures. If there is a conflict between the terms and conditions of this Agreement and the Quality Agreement, the terms and conditions of this Agreement shall prevail
except in quality related matters, where the Quality Agreement shall prevail. If the Quality Agreement is not in place at the Effective Date, Lonza and Customer commit to enter into the Quality Agreement in a timely manner, but in no event later
than [***]. 

  
 10 

Table of Contents

	4.2	 Provisions regarding inspections by Regulatory Authorities and audits shall be set out in the Quality
Agreement. 

  

	5	 Insurance 

  

	5.1	 Each Party shall, during the Term and for [***] ([***]) years after delivery of the last Product manufactured
or Services provided under this Agreement, obtain and maintain at its own cost and expense from a qualified insurance company, comprehensive general liability insurance including, but not limited to product liability coverage in the amount of at
least [***] per claim. Each Party shall provide the respective other Party with a certificate of such insurance upon reasonable request. 

  

	6	 Forecasting, Ordering and Cancellation 

 

	6.1	 Forecasting and Ordering. 

 

	 	6.1.1	 No later than the [***] ([***]) day of each [***] following the Effective Date of Agreement [***], Customer
shall supply Lonza with a written forecast showing Customer’s good faith estimated requirements for Batches to be delivered for the following [***] ([***]) [***] period, starting with the [***] (the “Forecast”). The Forecast shall
show a good faith estimate of the demand on a semi-annual basis for the non-binding period and the [***] demand for the Binding Forecast (as defined in Clause 6.1.2(a) below). The Parties acknowledge and agree
that as of the Effective Date Customer has provided Lonza with its initial forecast attached as Appendix C of Customer’s good faith estimated requirements for Batches to be manufactured in the Facility and such forecast shall be deemed a
Forecast. 

  

	 	6.1.2	 No later than [***] ([***]) days following Lonza’s receipt of a Forecast, Lonza shall provide written
notice to Customer of whether it has (as of the date of receipt of the Forecast) capacity available to manufacture the number of Batches forecasted therein and shall provide Customer with an estimated production schedule showing the estimated [***]
Date of each Batch. If upon receipt of a Forecast Lonza determines that it will not have sufficient capacity to meet the forecasted requirements, Lonza will promptly notify Customer and the parties will work together in good faith to determine how
to meet Customer’s requirements. 

  

	 	(a)	 The first [***] ([***]) [***] of any Forecast shall be binding (“Binding Forecast”). No Forecast
shall amend any previous Binding Forecast. [***]; 

  

	6.2	 Purchase Orders. 

 

	 	6.2.1	 Development Services. Customer shall place work orders for the Development Services it wishes to order
at least [***] ([***]) [***] or earlier as reasonably required prior to the Commencement Date for such Development Services, taking into consideration Lonza’s most recent Project Plan, provided that at all times the Parties shall use reasonable
endeavours to agree upon the time at which such Development Services will be performed. 

  

	 	6.2.2	 Manufacturing Services. Customer shall place binding purchase orders (“Purchase Orders”) for
manufacturing Campaigns in the Facility consistent to, and within [***] ([***]) days from, the most recent response by Lonza to the Forecast as per Clause 6.1.2 at least [***] ([***]) [***] prior to the estimated [***] Date for the first Batch of
such Campaign in accordance with Lonza’s most recent response to the respective Forecast. 

  
 11 

Table of Contents

	6.3	 Order Confirmation. Lonza shall confirm each Purchase Order within [***] ([***]) [***] days of
receipt from Customer of the relevant Purchase Order. For Batches manufactured for commercial use (excluding, for clarity, any Clinical Batches, Engineering Batches and Validation Batches) the Purchase Order shall set out the latest [***] Date(s)
and quantity of Product to be delivered. Upon confirmation, each Purchase Order will be regarded by the Parties as a binding commitment by Lonza to manufacture and to deliver to Customer the relevant number of Batches or to provide the Development
Services according to the requirements set out in such Purchase Order. Subject to Clause 6.4 any [***] Date set forth in Lonza’s written confirmation of a purchase order shall be the ultimate [***] Date of the first Batch of the Campaign,
allowing delivery up to [***] [***] earlier. All ordered Batches shall be scheduled in a single Campaign in each [***], excluding the first [***] ([***]) [***] after the Lonza Release of the last Process Validation Batch (forecast for the [***] of
the last batches of commercial campaigns may be up to [***] ([***]) [***] apart during this period), unless otherwise agreed by Lonza. Any additional or inconsistent terms or conditions of any Customer purchase order, acknowledgement or similar
standardized form given or received pursuant to this Agreement shall have no effect and such terms and conditions are hereby rejected. 

  

	6.4	 Rescheduling. Lonza shall have the right to reschedule a [***] Date of any Batch or Campaign upon
reasonable prior written notice to Customer, provided that (i) the rescheduled [***] Date is no later than [***] ([***]) days from the [***] Date originally estimated at the time of Lonza’s acceptance of the binding purchase order (the
“Original [***] Date”), and (ii) that the [***] Date of the first Batch of the Campaign is not to occur earlier than [***] ([***]) days before the Original [***] Date. If the Customer requests to change the [***] Date, Lonza will make
all reasonable attempts to accommodate the request; provided, however, in the event that this change would impact other projects scheduled for occupancy in the designated suite or suites, [***]. Any such change requested by Customer [***]. Any delay
requested by Customer of more than [***] ([***]) days shall be considered a cancellation pursuant to Clause 6.76. 

  

	6.5	 Minimum Quantity and Volume Commitments. Provided Customer has obtained Approval for the Drug Product
manufactured by using the Product from the Facility in the US or EU, Customer undertakes to purchase from Lonza and Lonza undertakes to be able to supply a minimum of at least [***] ([***]) Batches of Product manufactured [***] in one Campaign per
calendar year commencing in [***] (the “Minimum Quantity”). In addition, [***] Customer undertakes to purchase from Lonza at least [***] percent ([***]%) for the first [***] ([***]) years [***] and thereafter [***] percent
([***]%) of Customer’s annual requirement of Product beyond [***] kg and up to the lower of [***] ([***]) Batches or [***] kg starting with the [***] (the “Volume Commitment”). 

 

	6.6	 Failure to comply with Minimum Quantity and Volume Commitments. 

 

	 	6.6.1	 If Customer fails to purchase the Minimum Quantity, Customer shall pay the Price per Batch for the number of
Batches below the minimum within [***] ([***]) [***]. 

  

	 	6.6.2	 Within [***] ([***]) days of the end of each calendar year, [***]. In the event Lonza believes, [***], that the
Customer falls short of the Volume Commitment, [***]. 

  

	 	6.6.3	 Lonza commits to deliver to the Forecast, up to a maximum of [***] ([***]) Batches or of [***] kg per year,
whichever is lower, provided that it is within the 

  
 12 

Table of Contents

	 	
binding part of the Forecast. Such capacity may be reserved for the Customer for years [***] up to [***] of the Forecast. However, if another customer wishes to order such capacity in parts or
full, [***] 

  

	6.7	 Cancellation of a Binding Purchase Order. Customer may cancel a binding Purchase Order upon written
notice to Lonza, subject to the payment of a cancellation fee as calculated below (the “Cancellation Fee”): 

  

	 	6.7.1	 In the event that Customer provides written notice of cancellation to Lonza less than or equal to [***] ([***])
months prior to the [***] Date of one or more Batches [***], then [***] percent ([***]%) of the Batch Price of each such Batch cancelled is payable, provided that [***]; 

 

	 	6.7.2	 In the event that Customer provides written notice of cancellation to Lonza less than or equal to [***] ([***])
months prior to the [***] Date of [***], then [***] percent ([***]%) the Batch Price of each such Batch cancelled is payable, provided that [***]; and 

  

	 	6.7.3	 In the event that Customer provides written notice of cancellation to Lonza of more than [***] ([***]) months
prior to the [***] Date of one or more Batches, then no cancellation fee is due. 

  

	6.8	 Payment of Cancellation Fee. Any Cancellation Fee shall be payable latest by the original Commencement
Date associated with the cancelled Batch of Development or Manufacturing Service. Any Cancellation Fee shall include all documented costs associated with the cancelled Batch, including any Raw Materials, [***], Raw Materials Handling Fee and [***]
Handling Fee. 

  

	6.9	 Replacement Project. Notwithstanding the foregoing, Lonza will use commercially reasonable efforts to
secure a new or additional project (but excluding any project or production then under contract with Lonza with a [***] Date that is [***] ([***]) months or less after the notification date of the applicable cancellation or rescheduling by Customer)
for the development or manufacturing space, and for dates and duration that would have been occupied by Customer (a “New Project”). If Lonza is able to secure a New Project with Customer or another Lonza customer (the “Replacement
Services”), then, in such case, the Cancellation Fee for Development Services or Manufacturing Services cancelled that is replaced by a New Project shall be reduced or credited to Customer (if applicable) towards the New Project by an amount
equal to [***] percent ([***]%) of the respective Cancellation Fee pro-rated to the Facility occupancy (on a per diem basis) with such Replacement Services. . 

 

	6.10	 Enzymes. Unless otherwise specified in an amendment to this Agreement, the provisions of this Clause 6
shall also apply to the forecasting, ordering and cancelling of any enzyme, including [***], the Parties may mutually agree to be manufactured by Lonza. 

  

	7	 Delivery and Acceptance 

 

	7.1	 Acceptance/Rejection of Product. 

 

	 	7.1.1	 Lonza shall perform its own release of Batches (the “Lonza Release”). Promptly following the Lonza
Release of a Batch Lonza shall deliver to Customer the Certificate of Analysis, any other documentation as specified in the Quality Agreement, and such other documentation as is reasonably required and

  
 13 

Table of Contents

	 	
notified in advance by Customer to meet all applicable regulatory requirements of the Governmental Authorities. Customer shall review such Documentation and Lonza shall promptly answer all
questions from Customer and perform additional investigations as requested. Customer shall notify Lonza in writing of the final release (“Customer Release”) or rejection of the batch without undue delay. 

 

	 	7.1.2	 Promptly following the [***] Date of Batches, Customer shall inspect such Batches and shall have the right to
test such Batches to determine compliance with the Specifications. Customer shall notify Lonza in writing of any rejection of a Batch based on any claim that it fails to meet Specifications or comply with cGMP upon agreed procedures as agreed in the
Quality Agreement, but no later than within [***] ([***]) days of [***] Date, after which time all unrejected Batches shall be deemed accepted, except for concealed or latent defects. In case of concealed or latent defects discovered later, such
notification to be given in writing promptly upon discovery of such defects but, for concealed or latent defects, no later than [***] after Delivery of the Product. 

 

	 	7.1.3	 In the event that Lonza believes that a Batch has been incorrectly rejected, Lonza may require that Customer
provide to it Batch samples for testing. Lonza may retain and test the samples of such Batch. In the event of a discrepancy between Customer’s and Lonza’s test results such that Lonza’s test results fall within relevant
Specifications, or there exists a dispute between the Parties over the extent to which such failure is attributable to a given Party, the Parties shall cause an independent laboratory promptly to review records, test data and perform comparative
tests and analyses on samples of the Product that allegedly fails to conform to Specifications. Such independent laboratory shall be mutually agreed upon by the Parties. If the Parties are unable to agree on an independent laboratory, [***] shall
appoint such laboratory. The independent laboratory’s results shall be in writing and shall be final and binding [***]. Unless otherwise agreed to by the Parties in writing, the costs associated with such testing and review shall be borne by
the Party against whom the independent laboratory rules. 

  

	 	7.1.4	 Lonza shall reprocess free of charge any Batch or, if reprocessing is not possible, replace any Batch that
failed to conform with the Specifications or was not manufactured in compliance with cGMP (a “Failed Batch”), in the event that it is determined (by the Parties or the independent laboratory) that such failure was [***] (“Lonza
Responsibility”); in the event of [***]. Provided a Lonza Responsibility is confirmed, such reprocessing or replacement shall be made as promptly as practicable, in light of available manufacturing capacity and Raw Materials, and in any case as
soon as reasonably possible. [***] Customer acknowledges and agrees that its sole remedy with respect to a Failed Batch that is a Lonza Responsibility is as set forth in this Clause 7.1.4., and in furtherance thereof, Customer hereby waives all
other remedies at law or in equity regarding the foregoing claims.  

  

	7.2	 Delivery. All Product shall be delivered [***] (as defined by Incoterms® 2010) the Facility. Delivery is considered to have taken place when “Customer Release” has been notified to Lonza or [***] days after the Release by Lonza, whichever comes first. With
respect to any Customer Materials, title and risk of loss shall remain with the Customer and shall not transfer to Lonza, except as set forth in Clause 7.1.4 in case of a Failed Batch as a direct result of Lonza Responsibility. With respect to
Product and Raw Materials other than Customer Materials, title and risk of loss shall transfer to Customer upon Delivery. 

  
 14 

Table of Contents

	7.3	 Storage. Customer shall arrange for shipment and take delivery of such Batch from the Facility, at
Customer’s expense, within [***] ([***]) days after Customer Release or pay applicable storage costs. Lonza shall provide storage on a bill and hold basis for such Batch(es) at no charge for up to [***] ([***]) days; provided that any
additional storage beyond [***] ([***]) days will be charged on a monthly basis to Customer and may be subject to a separate agreement. In addition to Clause 8.2, Customer shall be responsible for all value added tax (VAT) and any other applicable
taxes, levies, import, duties and fees of whatever nature imposed as a result of any storage. Notwithstanding anything to the contrary contained in this Agreement, Lonza shall not be required to store any Batch for more than [***] ([***])
calendar days after Customer Release, [***], subject to availability and the applicable storage costs to be paid by Customer. Within [***] ([***]) days following a written request from Lonza, Customer shall provide Lonza with a letter [***]
confirming the [***] of each stored Batch. 

  

	8	 Price and Payment 

 

	8.1	 Pricing. Pricing for the Services provided by Lonza [***], any Scope Change or Work Order, and based on
the assumptions and information set out in, the applicable Project Plan. In the event of changes to the Services based on additional operational requirements or Customer’s request, Lonza and Customer shall discuss in good faith and agree on any
additional costs. [***] Any additional costs arising from [***] (including, without limitation Capital Equipment required for its implementation, methods of analysis, set-up cost or adjustments to Batch
pricing) shall be fully assumed by the Customer. 

  

	8.2	 Handling Fees. The Raw Materials Handling Fee shall be [***] percent ([***]%) and the [***] Handling Fee
shall be [***] percent ([***]%)[***]. 

  

	8.3	 Taxes. Unless otherwise indicated in writing by Lonza, all Prices and charges are exclusive of value
added tax (VAT) and of any other applicable taxes, levies, import, duties and fees of whatever nature imposed by or under the authority of any government or public authority and all such charges applicable to the Services shall be paid by Customer.
When sending payment to Lonza, the Customer shall quote the relevant invoice number in its remittance advice. 

  

	8.4	 Invoicing. Lonza shall issue invoices to Customer as follows: 

 

	 	8.4.1	 All Development Services and Manufacturing Services shall be invoiced as follows: 

 

	 	-	 [***] percent ([***]%) of the Price for all Batches or Services upon the [***] Date of such Batch or Service;
and 

  

	 	-	 [***] percent ([***]%) upon [***] Date of each Batch or completion of applicable Services.

  

	 	8.4.2	 Charges for Raw Materials and the Raw Materials Handling Fee for each Batch shall be invoiced as follows:

  

	 	-	 [***] 

  

	 	8.4.3	 Purchase cost for [***] shall be invoiced by Lonza at [***]% of the [***] cost and [***] Handling Fee upon the
date the applicable Purchase Order is accepted by Lonza, but no earlier than Lonza issuing the purchase order to its [***] supplier. 

  
 15 

Table of Contents

 All invoices are strictly net and payment for amounts not subject to a bona fide dispute
must be made within [***] ([***]) days of Customer’s receipt of the applicable invoice, without deduction, deferment, set-off, lien or counterclaim. 

 

	8.5	 Payment Default. If in default of payment of any undisputed invoice on the due date, interest shall
accrue on any amount overdue at the lesser of (i) rate of [***] or (ii) the maximum rate allowable by law governing this Agreement, interest to accrue on a day to day basis until full payment; and Lonza shall, at its sole
discretion, and without prejudice to any other of its accrued rights, be entitled to suspend the provision of the Services and or delivery of Product until all overdue amounts have been paid in full including interest for late payments.

  

	8.6	 Price adjustments. 

 

	 	8.6.1	 Not more than once per calendar year, starting [***], Lonza may, by notification sent no later than [***] of
the prior year, adjust the Price in accordance with the [***] (or any successor index) increase for the previous calendar year (there is no decrease if the [***] goes down provided, however, that in the event of a decrease of such index an
adjustment shall only be possible after such index has exceeded the index position on which the last adjustment was based). The new Price reflecting such Batch Price adjustment shall be effective for any Batch for which the Commencement Date is on
or after the date of Lonza’s notice to Customer of the Price adjustment. 

  

	 	8.6.2	 In addition to the above, the Price may be changed by Lonza, upon reasonable prior written notice to Customer
(providing reasonable detail in support thereof), to reflect (i) [***], or for a [***], and (ii) [***]. 

  

	 	8.6.3	 The Parties will work together to jointly develop a continuous improvement plan in order to achieve cost
reductions for validated processes. Customer shall benefit fully from improvements initiated and developed by Customer and transferred to Lonza. In respect of any Modified Manufacturing Process resulting from jointly initiated and/or performed
improvements Customer shall benefit by [***] percent ([***]%) of the improvement so derived. Lonza shall retain all benefits of any Modified Manufacturing Process to extent Customer did neither initiate nor participate in the improvement or
modification. 

  

	9	 Capital Equipment 

 

	9.1	 Any Capital Equipment required for the performance of the Services shall be acquired on terms to be agreed by
the Parties prior to the Commencement Date of the relevant Services it being understood that irrespective of such terms the capital equipment will be the sole property of Lonza. Any Capex funded by Lonza for such Capital Equipment, upon
Customer’s request and pre-approval of the cost thereof in writing, shall be reimbursed by Customer [***]. 

  

	9.2	 [***]. 

  

	9.3	 Any Capital Equipment required to [***] will be funded by Customer, but shall remain subject to [***].

  

	10	 Intellectual Property 

 

	10.1	 Background Intellectual Property 

  
 16 

Table of Contents

	 	10.1.1	 Except as expressly otherwise provided herein, neither Party will, as a result of this Agreement, acquire any
right, title, or interest in any Background Intellectual Property of the other Party, including any improvements made thereto during the performance of the Services under this Agreement. 

 

	10.2	 New Intellectual Property Ownership 

 

	 	10.2.1	 [***] Ownership. Subject to Clause 10.3, [***] develop, conceive, invent, first reduce to practice or make,
solely or jointly with [***], in the course of the [***], to the extent that is both: 

  

	 	(i)	 a derivative of or improvement to [***], and 

 

	 	(ii)	 [***]. For avoidance of doubt, [***] shall include any [***], but excluding any [***] 

 

	 	10.2.2	 [***] Ownership. Notwithstanding Clause 10.2.1, [***], develop, conceive, invent, or first reduce to practice
or make solely or jointly with [***], in the course of [***] that is generally applicable to the [***]. For avoidance of doubt, [***] shall include any [***] 

  

	 	10.2.3	 Assignment of New Intellectual Property. [***] hereby assigns to [***] all of its right, title and interest in
any [***]. To the extent that [***] has or obtains any rights, title or interest in [***] hereby assigns to [***] all of its right, title and interest in any [***]. 

 

	10.3	 License Grants. 

  

	 	10.3.1	 Subject to the terms and conditions set forth herein (including the payment of the Price as required above),
Lonza hereby grants to Customer a [***] 

  

	 	10.3.2	 Customer hereby grants Lonza and its Affiliates, sub-contractors and
the External Laboratories the [***] solely for the purpose of fulfilling its obligations under this Agreement. 

  

	 	10.3.3	 Unless the Parties expressly, mutually agree to the contrary herein in writing, including without limitation by
express reference to a given OtherAgreement (defined below), nothing in this Agreement (or any Project Plan entered into pursuant to this Agreement) shall supersede, amend or otherwise modify any terms or conditions or other provisions of any other
agreement between the Parties that is entered into prior to or contemporaneously with the execution of this Agreement, including, without limitation, any agreement related to any [***], or any services performed by Lonza or any Affiliate of Lonza
for Customer, or any consumables or other products supplied by Lonza or any Affiliate to Customer (collectively, an “Other Agreement”). 

  

	10.4	 Technology Transfer to Customer or Third Party Manufacturer. 

 

	 	10.4.1	 Upon the written notification by Customer to Lonza and subject to the terms and conditions of this Clause 10.4
[***], and [***], and [***], Customer will be permitted to transfer the Manufacturing Process to itself and/or any Third Party manufacturer for the manufacture of the Product or, to the extent agreed by the Parties, the [***] (but no other product)
at a particular site. For the avoidance of any doubt [***]. 

  
 17 

Table of Contents

	 	    	 Customer shall provide written notice to Lonza at least [***] ([***]) days in advance that it wishes to
exercise its rights under this Clause 10.4 (the “Technology Transfer Notice”). The Technology Transfer Notice shall provide reasonable details to Lonza about [***]. In the case of a proposed transfer of the Manufacturing Process to a Third
Party, Customer shall indicate details about [***] 

  

	 	10.4.2	 If the Technology Transfer Notice is [***], Lonza’s consent to such requested transfer shall not be
unreasonably withheld or delayed. If the Technology Transfer Notice is [***], (i) Customer must seek and obtain from Lonza approval for such transfer prior to any such transfer [***], and (ii) the Parties shall, agree on terms governing such
technology transfer, including [***] 

  

	 	10.4.3	 Lonza shall not be obliged to transfer any Modified Manufacturing Process to any Third Party (a) [***], and/or
(b) [***]. 

  

	 	    	 For any transfer under this Clause 10.4, Lonza shall provide reasonably necessary documents (including the
Product-specific Batch Records, deviations, root cause analyses, and release reports, technology transfer guidance and summary report and process protocols) to complete such technology transfer and [***] 

 

	10.5	 Prosecution of Patents. 

 

	 	10.5.1	 Subject to the following subsection, Customer will have the sole right and discretion to file (or not file),
prosecute and maintain patent applications and patents claiming the New Customer Intellectual Property, at Customer’s expense. Lonza will cooperate with Customer, at Customer’s expense, to file, prosecute, maintain, defend, and enforce
patent applications and patents claiming any New Customer Intellectual Property. 

  

	 	10.5.2	 Unless the Parties agree otherwise, at least [***] ([***]) days prior to [***]. Within [***] ([***]) days of
receipt of [***]. As determined by Lonza, [***] 

  

	 	10.5.3	 Lonza will have the sole right and discretion to file (or not file), prosecute and maintain patent applications
and patents claiming the New General Application Intellectual Property, at Lonza’s expense. Customer will cooperate with Lonza[***] to file, prosecute, maintain, defend, and enforce patent applications and patents claiming any New General
Application Intellectual Property. 

  

	11	 Warranties 

  

	11.1	 Lonza warrants that: 

 

	 	11.1.1	 the Services shall be performed in accordance with all Applicable Laws; 

 

	 	11.1.2	 except with respect to any development services and Engineering Batches, the manufacture of Product shall be
performed in accordance with cGMP and will meet the Specifications at the date of Delivery; 

  

	 	11.1.3	 it or its Affiliates hold all necessary permits, approvals, consents and licenses to enable it to perform the
Services at the Facility, except to the extent that failure to maintain such licenses, permits and approvals do not have a material adverse impact on the ability to manufacture the Product in the Facility, or on the Services provided under this
Agreement; 

  
 18 

Table of Contents

	 	11.1.4	 to its knowledge, the conduct and the provision of the Services shall not infringe, misappropriate or violate
(as the case may be) any proprietary or Intellectual Property rights of any Third Party; 

  

	 	11.1.5	 it shall promptly notify Customer in writing if it receives or is notified of a formal written claim from a
Third Party that Lonza Information, Lonza Background Intellectual Property or New General Application Intellectual Property, as it relates to the Services under this Agreement, or that the use by Customer thereof, to the extent permitted under this
Agreement, infringes, misappropriates or violates (as the case may be) any proprietary or Intellectual Property rights of any Third Party; and 

  

	 	11.1.6	 it has the necessary corporate authorizations to enter into and perform this Agreement. 

 

	11.2	 Customer warrants that: 

 

	 	11.2.1	 it has to the best of its knowledge as of the Effective Date all the rights necessary to permit Lonza to
perform the Services without infringing the Intellectual Property rights of any Third Party and the performance of the Services shall to the best of Customer’s knowledge as of the Effective Date not infringe, misappropriate or violate (as the
case may be) any proprietary or Intellectual Property rights of any Third Party; 

  

	 	11.2.2	 all Customer Materials shall be provided with a certificate of analysis or other relevant documentation
demonstrating that such Customer Materials meet the following Lonza acceptance criteria: (i) [***], (ii) [***], (iii) [***], (iv) [***], and (v) [***]. In addition, [***], and will update, clarify, correct, supplement and amend such information as
necessary; 

  

	 	11.2.3	 it will promptly notify Lonza in writing if it receives or is notified of a formal written claim from a Third
Party that Customer Information and Customer Intellectual Property or that the use by Lonza thereof for the provision of the Services infringes, misappropriates or violates (as the case may be) any proprietary or Intellectual Property or other
rights of any Third Party; 

  

	 	11.2.4	 in connection with its receipt and usage of the Services and Products, Customer shall [***]. Customer shall
[***]. Customer confirms that [***]; and 

  

	 	11.2.5	 it has the necessary corporate authorizations to enter into this Agreement. 

 

	11.3	 DISCLAIMER: THE WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT ARE IN LIEU OF ALL OTHER WARRANTIES,
AND ALL OTHER WARRANTIES, BOTH EXPRESS AND IMPLIED, ARE EXPRESSLY DISCLAIMED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

 

	12	 Indemnification and Liability 

 

	12.1	 Indemnification by Lonza. Lonza shall indemnify the Customer, its Affiliates, and their respective
officers, employees and agents (“Customer Indemnitees”) for any loss, damage, costs and expenses (including reasonable attorney fees) that Customer Indemnitees may suffer as a result of any Third Party claim arising directly out of (i)
[***] or (ii) [***] 

  
 19 

Table of Contents

	12.2	 Indemnification by Customer. Customer shall indemnify Lonza, its Affiliates, and their respective
officers, employees and agents (“Lonza Indemnitees”) from and against any loss, damage, costs and expenses (including reasonable attorney fees) that Lonza Indemnitees may suffer as a result of any Third Party claim arising directly out of
(i) [***]; or (ii) [***] 

  

	12.3	 Indemnification Procedure. If the Party to be indemnified intends to claim indemnification under this
Clause 12, it shall promptly notify the indemnifying Party in writing of such claim. The indemnitor shall have the right to control the defense and settlement thereof; provided, however, that any indemnitee shall have the right to retain its own
counsel at its own expense. The indemnitee, its employees and agents, shall reasonably cooperate with the indemnitor in the investigation of any liability covered by this Clause 12. The failure to deliver prompt written notice to the indemnitor of
any claim, to the extent prejudicial to its ability to defend such claim, shall relieve the indemnitor of any obligation to the indemnitee under this Clause 12. 

 

	12.4	 Recall. 

  

	 	12.4.1	 If the Customer is required by a Regulatory Authority or voluntarily chooses to initiate a recall
(“Recall”) or withdrawal of any Drug Product, the Customer shall notify Lonza. 

  

	 	12.4.2	 Lonza shall provide all reasonably requested assistance and information to Customers and cooperate with the
Customer to implement the Recall in accordance with the protocols and procedures contained in the Quality Agreement. 

  

	 	12.4.3	 [***] 

  

	 	12.4.4	 [***] 

  

	12.5	 DISCLAIMER OF CONSEQUENTIAL DAMAGES. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR
INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES, LOST PROFITS OR LOST REVENUES ARISING FROM OR RELATED TO THIS AGREEMENT, EXCEPT TO THE EXTENT RESULTING FROM FRAUD, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT. 

 

	12.6	 LIMITATION OF LIABILITY. LONZA’S LIABILITY UNDER THIS AGREEMENT SHALL IN NO EVENT EXCEED, IN THE
AGGREGATE, [***] TOTAL AMOUNTS PAID BY CUSTOMER TO LONZA [***] IN THE [***] PERIOD PRECEDING THE FIRST CLAIM FOR DAMAGES, EXCEPT TO THE EXTENT RESULTING FROM [***] 

 

	13	 Confidentiality 

 

	13.1	 A Party receiving Confidential Information (the “Receiving Party”) agrees to strictly keep secret any
and all Confidential Information received during the Term from or on behalf of the other Party (the “Disclosing Party”) using at least the same level of measures as it uses to protect its own Confidential Information, but in any case at
least commercially reasonable and customary efforts. Confidential Information shall include information disclosed in any form including but not limited to in writing, orally, graphically or in electronic or other form to the Receiving Party,
observed by the 

  
 20 

Table of Contents

	 	
Receiving Party or its employees, agents, consultants, or representatives, or otherwise learned by the Receiving Party under this Agreement, which the Receiving Party knows or reasonably should
know is confidential or proprietary. 

  

	13.2	 Notwithstanding the foregoing, Receiving Party may disclose to any courts and/or other Governmental Authorities
Confidential Information which is or will be required pursuant to applicable governmental or administrative or public law, rule, regulation or order. In such case the Party that received the Confidential Information will, to the extent legally
permitted, inform the other Party promptly in writing and cooperate with the Disclosing Party in seeking to minimize the extent of Confidential Information which is required to be disclosed to the courts and/or authorities. 

 

	13.3	 The obligation to maintain confidentiality under this Agreement does not apply to Confidential Information,
which: 

  

	 	13.3.1	 at the time of disclosure was publicly available; or 

 

	 	13.3.2	 is or becomes publicly available other than as a result of a breach of this Agreement by the Receiving Party;
or 

  

	 	13.3.3	 as the Receiving Party can establish by competent proof, was rightfully in its possession at the time of
disclosure by the Disclosing Party and had not been received from or on behalf of Disclosing Party; or 

  

	 	13.3.4	 is supplied to a Party by a Third Party which was not in breach of an obligation of confidentiality to
Disclosing Party or any other party; or 

  

	 	13.3.5	 is developed by or on behalf of the Receiving Party independently from and without use of the Confidential
Information, as evidenced by Receiving Party’s contemporaneous written records. 

  

	13.4	 The Receiving Party will use Confidential Information only for the purposes of this Agreement and will not make
any use of the Confidential Information for its own separate benefit or the benefit of any Third Party including, without limitation, with respect to research or product development or any reverse engineering or similar testing. The Receiving Party
agrees to return or destroy promptly (and certify such destruction) on Disclosing Party’s request all written or tangible Confidential Information of the Disclosing Party, except that one copy of such Confidential Information may be kept by the
Receiving Party in its confidential files for record keeping purposes only. 

  

	13.5	 Each Party will restrict the disclosure of Confidential Information to such officers, employees, consultants
and representatives of itself and its Affiliates who have been informed of the confidential nature of the Confidential Information and who have a need to know such Confidential Information for the purpose of this Agreement. Prior to disclosure to
such persons, the Receiving Party shall bind its and its Affiliates’ officers, employees, consultants and representatives to confidentiality and non-use obligations no less stringent than those set forth
herein. The Receiving Party shall notify the Disclosing Party as promptly as practicable of any unauthorized use or disclosure of the Confidential Information. 

 

	13.6	 The Receiving Party shall at any time be fully liable for any and all breaches of the confidentiality
obligations in this Clause 13 by any of its Affiliates or the employees, Subcontractors, consultants and representatives of itself or its Affiliates. 

  
 21 

Table of Contents

	13.7	 Each Party hereto expressly agrees that any breach or threatened breach of the undertakings of confidentiality
provided under this Clause 13 by a Party may cause irreparable harm to the other Party and that money damages may not provide a sufficient remedy to the non-breaching Party for any breach or threatened breach.
In the event of any breach and/or threatened breach, then, in addition to all other remedies available at law or in equity, the non-breaching Party shall be entitled to seek injunctive relief and any other
relief deemed appropriate by the non-breaching Party. 

  

	14	 Compliance 

  

	14.1	 Lonza undertakes to conduct its business in accordance with all applicable laws and regulations and the
principles in the Lonza Code of Conduct as can be found online at
https://www.lonza.com/about-lonza/global-citizenship/ethics-and-compliance/code-of-conduct.asp.
 

  

	14.2	 Either Party is committed to maintaining high standards of ethical conduct and will not tolerate the use of
bribery or corruption to achieve its business objectives. Thus, Lonza and Customer, including their affiliates, and their directors, employees, agents, representatives, contractors or sub-contractors, shall
comply at all times with all applicable anti-bribery laws, rules and regulations (including but not limited to the UK Bribery Act and the United States Foreign Corrupt Practices Act (FCPA)) as well as any and all International Trade Restrictions.
For the avoidance of doubt, this will include, not offering or giving a financial or other advantage with the intention of influencing in connection with the performance of the duties to obtain or retain a business advantage for Customer.

  

	14.3	 Each Party shall (and shall procure that its affiliates shall) have in place adequate procedures designed to
prevent any person working for or engaged by such Party and its affiliates or any other third party in any way connected to this Agreement, from engaging in any activity, practice or conduct which would infringe any anti-bribery and anti-corruption
laws, regulations and codes, including but not limited to the UK Bribery Act 2010 and the FCPA. 

  

	14.4	 Each Party and its representatives shall at all times and promptly take all appropriate steps to resolve and
correct any identified non-conformity. [***]. Subject to Clause 12, [***]. 

  

	14.5	 Upon request of a Party, the other Party shall promptly provide reasonably detailed information on its level of
compliance with this Clause 14 so that the requesting Party can assess whether the other Party complies with the requirements or not. 

  

	15	 Term and Termination 

 

	15.1	 Term. This Agreement shall commence on the Effective Date and, unless earlier terminated or extended by
the Parties in accordance herewith (subject to the rights of early termination set out herein), shall continue in effect until the seventh (7th) anniversary of the first regulatory approval of the
Drug Product manufactured by using the Product in the earlier of EU or the US (the “Initial Term”). Until two (2) years before the end of the Initial Term (i.e. estimated as [***]), Customer shall have the option, upon notification to
Lonza, to extend the Agreement with another two (2) year term (“Renewal Term”) after expiry of the Initial Term (i.e. until approximately December 31, 2031). The Initial Term, together with the Renewal Term, if applicable, shall
be defined as the “Term”. Notwithstanding the foregoing, each Project Plan or work order may have separate term and termination provisions. 

  
 22 

Table of Contents

	15.2	 Termination. This Agreement may be terminated as follows: 

 

	 	15.2.1	 by either Party if the other Party breaches a material provision of this Agreement or a Project Plan and fails
to cure such breach to the reasonable satisfaction of the non-breaching Party within [***] ([***]) days ([***] ([***]) days for non-payment) following written
notification of such breach from the non-breaching party to the breaching party; provided, however, that such [***] ([***]) day period shall be extended as agreed by the Parties if the identified breach is
incapable of cure within [***] ([***]) days and if the breaching Party provides a plan and timeline to cure the breach, promptly commences efforts to cure the breach and diligently prosecutes such cure (it being understood that this extended period
shall be unavailable for any breach regarding non-payment); 

  

	 	15.2.2	 by either Party, immediately, if the other Party becomes insolvent, is dissolved or liquidated, makes a general
assignment for the benefit of its creditors, or files or has filed against it, a petition in bankruptcy or has a receiver appointed for a substantial part of its assets; 

 

	 	15.2.3	 by either Party pursuant to Clause 16; 

 

	 	15.2.4	 by either Party with [***] ([***]) months’ prior written notice, within [***] days following a Change of
Control of the Customer, provided that (a) during such [***] ([***]) [***] period, Customer may place, and Lonza will accept, binding Purchase Orders in accordance with the provisions of Section 6.2, and (b) all Purchase Orders
binding the Parties as of the end of such [***] ([***]) month period will remain binding on the Parties subject to the terms and conditions of Section 6 and (c) Customer shall remain to be bound by Section 6.5 and 6.6. For purposes of
this section 15.2.4 “Change of Control” means the occurrence of any of the following with respect to Customer at any time after the date hereof: (a) a merger, reorganization or consolidation of Customer with a third party which
results in the voting securities of Customer outstanding immediately prior thereto ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization or consolidation;
or (b) a third party person or group of persons becoming the direct or beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding shares of common stock or other type of voting securities of Customer; or
(c) the sale or other transfer of all or substantially all of Customer’s assets which relate to this Agreement to a third party. Notwithstanding the foregoing, an internal reorganization or consolidation among Customer and its Affiliates
shall not be deemed a Change of Control for purposes of this Agreement; 

  

	 	15.2.5	 by Lonza by written notice if, [***], Lonza determines that in respect of the Product [***] (i) [***] and/or
(ii) [***]. The termination right as per this Clause 15.2.5 is valid until [***] only, subject to an extension to be mutually agreed upon. After [***] (or any extension date agreed in this respect), Lonza shall have no right to terminate this
Agreement on grounds [***] pursuant to this Clause 15.2.5; or 

  

	 	15.2.6	 by the Customer by written notice, if Customer can demonstrate [***]. The termination right as per this Clause
15.2.6 is valid only if given [***], subject to an extension to be mutually agreed upon. After any notification to [***] or [***] (or any extension date agreed in this respect), Customer shall have no right to terminate this Agreement on grounds of
[***]. 

  
 23 

Table of Contents

	15.3	 Consequences of Termination. In the event of termination hereunder, Lonza shall be compensated for (i)
[***]; (ii) [***]; (iii) [***]; (iv) [***] and (v) [***]. In the case of termination by Lonza for Customer’s material breach, [***]. [***] if the Agreement is rightfully terminated in accordance with Clauses 15.2.5 or 15.2.6. If Lonza
terminates this Agreement due to Customer’s breach or insolvency in accordance with Clause 15.2.1 or 15.2.2, [***]. If the Customer terminates this Agreement due to Lonza’s breach or insolvency in accordance with Clause 15.2.1 or 15.2.2,
[***]. 

  

	15.4	 Survival. The rights and obligations of each Party which by their nature survive the termination or
expiration of this Agreement shall survive the termination or expiration of this Agreement, including Clauses 5, 10-13 and 17 (to the extent relevant). 

 

	16	 Force Majeure 

 

	16.1	 If Lonza is prevented or delayed in the performance of any of its obligations under the Agreement by Force
Majeure and gives written notice thereof to Customer specifying the matters constituting Force Majeure together with such evidence as Lonza reasonably can give and specifying the period for which it is estimated that such prevention or delay will
continue, Lonza shall be excused from the performance or the punctual performance of such obligations as the case may be from the date of such notice for so long as such cause of prevention or delay shall continue. Provided that, if such Force
Majeure persists for a period of [***] ([***]) months or more, Customer may terminate this Agreement by delivering written notice to Lonza. 

  

	16.2	 “Force Majeure” shall be deemed to include any reason or cause beyond Lonza’s reasonable control
affecting the performance by Lonza of its obligations under the Agreement, including, but not limited to, any cause arising from or attributable to acts of God, strike, lockouts, labor troubles, restrictive governmental orders or decrees, riots,
insurrection, war, terrorists acts, or the inability of Lonza to obtain any required raw material, energy source, equipment or labor. 

  

	16.3	 With regard to Lonza, any such event of Force Majeure affecting services or production at its Affiliates or
suppliers shall be regarded as an event of Force Majeure. 

  

	17	 Miscellaneous 

 

	17.1	 Severability. If any provision hereof is or becomes at any time illegal, invalid or unenforceable in any
respect, neither the legality, validity nor enforceability of the remaining provisions hereof shall in any way be affected or impaired thereby. The Parties hereto undertake to substitute any illegal, invalid or unenforceable provision by a provision
which is as far as possible commercially equivalent considering the legal interests and the Purpose. 

  

	17.2	 Amendments/Assignment. Modifications and/or amendments of this Agreement must be in writing and signed
by the Parties. Lonza shall be entitled to instruct one or more of its Affiliates to perform any of Lonza’s obligations contained in this Agreement, but Lonza shall remain fully responsible in respect of those obligations. Subject thereto,
neither Party may assign its interest under this Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed, provided, however that (a) Lonza may assign this Agreement to
(i) any Affiliate of Lonza or (ii) any third party, other than a competitor of Customer, being [***], in connection with the sale or transfer (by whatever method) of all or substantially all of the assets of the business related to the
Facility or providing the Services, and (b) Lonza shall be entitled to sell, assign and/or transfer its trade receivables resulting 

  
 24 

Table of Contents

	 	
from this Agreement without the consent of the Customer. Customer is free to assign its rights and obligations, including (without limitation) to a third party acquiring, by purchase or license,
rights to further develop or commercialize Customer’s [***] product, except to [***]. For purposes of this Clause 17.2, the terms “assign” and “assignment” shall include, without limitation (i) the sale of fifty percent
(50%) or more of the outstanding stock of such Party to an Affiliate of such Party or an unrelated entity or natural person, (ii) the sale or transfer or other assignment of all or substantially all of the assets of the Party or the line of
business or Product to which this Agreement relates, and (iii) a merger, consolidation, acquisition or other form of business combination. Any purported assignment without a required consent shall be void. No assignment shall relieve any Party
of responsibility for the performance of any obligation that accrued prior to the effective date of such assignment. 

  

	17.3	 No Presumption Against Drafter. Each Party and its legal counsel have reviewed and revised this
Agreement. The rule of construction that requires that ambiguities in this Agreement (including any Appendix hereto) be construed against the drafter shall be waived by both Parties in the interpretation of this Agreement. 

 

	17.4	 Notice. All notices must be written and sent to the address of the Party first set forth above.
All notices must be given (a) by personal delivery, with receipt acknowledged, (b) by prepaid certified or registered mail, return receipt requested, or (c) by prepaid recognized next business day delivery service. Notices will be
effective upon receipt or at a later date stated in the notice. 

  

	17.5	 Governing Law/Jurisdiction. This Agreement is governed in all respects by the laws of Switzerland
without regard to its conflicts of laws principles. The United Nations Convention on Contracts for the International Sales of Goods is expressly disclaimed. The Parties agree to submit to the exclusive jurisdiction of the courts of [***].

  

	17.6	 Entire Agreement. This Agreement contains the entire agreement between the Parties as to the subject
matter hereof and supersedes all prior and contemporaneous agreements with respect to the subject matter hereof. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together
shall constitute one and the same document. Each party acknowledges that an original signature or a copy thereof transmitted by .pdf shall constitute an original signature for purposes of this Agreement. 

  
 25 

Table of Contents

 IN WITNESS WHEREOF, each of the Parties hereto has caused this Tech Transfer and
Manufacturing Services Agreement to be executed by its duly authorized representative effective as of the date written above. 
  

			
	LONZA LTD
		
	 By:
	 	 /s/ Clemens Jakobi

		 	Name Clemens Jakobi
		 	Title Director, Commercial Director
		
	 By:
	 	 /s/ Michael Stanek

		 	Name Michael Stanek
		 	Title General Counsel
	
	ASCENDIS PHARMA A/S
		
	 By:
	 	 /s/ Jan Møller Mikkelsen

		 	Name Jan Møller Mikkelsen
		 	Title CEO
	
	ASCENDIS PHARMA A/S
		
	 By:
	 	 /s/ Michael Wolff Jensen

		 	Name Michael Wolff Jensen
		 	Title Chief Legal Officer

Table of Contents

 APPENDIX A 

Project Plan 

APPENDIX B 

Specifications 

APPENDIX C 

Initial Forecast as of the Effective Date 

APPENDIX D 

Prices 

APPENDIX E 
 Raw
Materials 
 APPENDIX F 

CAPEX 

APPENDIX G 

Roadmap Cleanability 

APPENDIX H 

QUALITY AGREEMENT 

(To be attached to the Agreement after finalization by the Parties) 

Table of Contents

 APPENDIX A 

Project Plan 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

Table of Contents

 APPENDIX B 

Specifications 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

Table of Contents

 APPENDIX C 

Initial Forecast as of the Effective Date 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

Table of Contents

 APPENDIX D 

Prices 
 Omitted
pursuant to Regulation S-K, Item 601(a)(5) 

Table of Contents

 APPENDIX E 

Raw Materials 

(Bill of Materials) 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

Table of Contents

 APPENDIX F 

CAPEX 
 Omitted
pursuant to Regulation S-K, Item 601(a)(5) 

Table of Contents

 APPENDIX G 

Roadmap Cleanability 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

Table of Contents

 APPENDIX H 

QUALITY AGREEMENT 

Omitted pursuant to Regulation S-K, Item 601(a)(5)EX-4.17

 Exhibit 4.17 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such
excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
 PACKAGING
AND SUPPLY AGREEMENT 
 This Packaging and Supply Agreement (the “Agreement”) effective as of December 1, 2019 (the
“Effective Date”), is entered into by and between Sharp Corporation, a corporation organized and existing under the laws of Pennsylvania having its principal office at 7451 Keebler Way, Allentown, Pennsylvania 18106 (“Sharp”) and
Ascendis Pharma A/S, a corporation organized and existing under the laws of Denmark having its principal office at Tuborg Boulevard 12, 2900 Hellerup, Denmark (“Ascendis”) (hereinafter individually referred to as “Party” and
collectively as “the Parties”). 
 WITNESSETH: 

WHEREAS, Ascendis desires to engage Sharp on a non-exclusive basis, to package the Product(s) (as
defined below) and supply to Ascendis the Packaged Products (as defined below); and 
 WHEREAS, Sharp desires to accept such engagement
under the terms and conditions set forth in this Agreement 
 NOW, THEREFORE, in consideration of these premises and the covenants,
agreements and stipulations hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows: 

Definitions 
  

	 	1.1.	 “Affiliates” shall mean, any entities or persons directly or indirectly controlling, controlled by,
or under common control with a party, where “controlled,” “controlled by,” and “under common control with” means the direct or indirect ability or power to direct or cause the direction of management policies of such
entity or otherwise direct the affairs of such entity or person, whether through ownership of voting securities, by contract or otherwise. 

  

	 	1.2.	 “Applicable Law” shall mean the FDCA (as defined below) and all other laws, regulations, rules and
guidelines promulgated by a Regulatory Authority in Exhibit E, Territory (as defined below), relating to the packaging of the Products and the storage and transportation of the Products or Packaged Products, including, but not limited to, current
Good Manufacturing Practices (“cGMP”) as specified in the United States Code of Federal Regulations, as amended from time to time. For purposes of this Agreement, the parties acknowledge and agree that notwithstanding anything to the
contrary herein contained, [***]. 

	 	1.3.	 “Brand Image” shall have the meaning set forth in Section 9.1. 

 

	 	1.4.	 “Carrier” or “Ascendis Carrier” shall mean a carrier engaged by Ascendis to ship Products
in accordance with Section 6.2. 

  

	 	1.5.	 “Delivery” shall mean the transfer of Packaged Product at the point where risk and responsibility is
transferred from Sharp to Ascendis according to the agreed Inco Terms, which shall be [***], [***]. 

  

	 	1.6.	 “EMA” shall mean the European Medicines Agency, and any successor agency having substantially the
same functions. 

  

	 	1.7.	 “Facilities” shall mean Sharp’s manufacturing facilities located at [***], and [***], and [***]
and/or any other facility as may be designated by Sharp from time to time during the Term (as defined below) and approved by the Ascendis for use. 

  

	 	1.8.	 “FDA” shall mean the United States Food and Drug Administration, and any successor agency having
substantially the same functions. 

  

	 	1.9.	 “FDCA” shall mean the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§ 321
et seq., as amended from time to time. 

  

	 	1.10.	 “Firm Order” shall mean a firm order as described in Section 5.2(b). 

 

	 	1.11.	 “Forecast” shall have the meaning set forth in Section 5.2(a). 

 

	 	1.12.	 “Packaging Materials” shall mean the components and other materials utilized by Sharp in connection
with the packaging of the Products, which shall either be supplied by Ascendis or purchased by Sharp on Ascendis’ behalf. 

  

	 	1.13.	 “Packaged Product(s)” shall mean the Products in packaged form. 

 

	 	1.14.	 “Price” shall mean the price to be paid by Ascendis to Sharp for the Packaged Products and related
services as set forth on Exhibit A, as may be adjusted in accordance with Section 6.1. 

  

	 	1.15.	 “Products” shall mean the products described on Exhibit A to be manufactured by or on behalf of
Ascendis and shipped in bulk to Sharp for packaging. Upon the parties’ mutual written consent, the parties may from time to time during the Term amend Exhibit A to remove, add or substitute Products. 

 

	 	1.16.	 “Purchase Order” shall have the meaning set forth in Section 5.2(b). 

 

	 	1.17.	 “Quality Agreement” shall have the meaning set forth in Section 7.1. 

 

	 	1.18.	 “Regulatory Authority” shall mean any federal, state or local governmental regulatory authority in
the Territory involved in regulating any aspect of the 

  
 2 

	 	
development, market approval, sale, distribution or use of the Product, the Packaging Materials or the Packaged Product. For purposes of this Agreement, the parties acknowledge and agree that
notwithstanding anything to the contrary herein contained, [***]. 

  

	 	1.19.	 “Revised Purchase Order” shall have the meaning set forth in Section 5.2(b).

  

	 	1.20.	 “Specifications” shall mean the specifications, provided by Ascendis to Sharp, to be followed by
Sharp in connection with obtaining and using the Packaging Materials and the storage, labeling and packaging of the Products and the storage and supply of the Packaged Products. The Specifications are attached hereto as Exhibit B.

  

	 	1.21.	 “Start-Up Activities” shall have the meaning set forth in
Section 4.1. 

  

	 	1.22.	 “Term,” “Initial Term” and “Subsequent Term” shall have the meanings set forth in
Section 12.1. 

  

	 	1.23.	 “Territory” shall mean the countries listed in Exhibit E. More countries may be added to the
Territory later upon mutual agreement. 

  

	 	1.24.	 “Tooling” shall mean the tooling made for the packaging, assembly, and labeling of the Products.

 The definitions in this Article 1 shall apply equally to both the singular and plural forms of the terms defined. The
words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” All references herein to Sections and Exhibits shall be deemed references to Sections of this
Agreement and Exhibits to this Agreement unless the context shall otherwise require. 
  

	2.	 Nature of Engagement 

2.1    Engagement. Ascendis hereby engages Sharp, and Sharp hereby accepts Ascendis’ engagement, as
Ascendis’ service provider to store, package, assemble, and label the Products and store and supply the Packaged Products for commercial use within the Territory in accordance with the Specifications and the terms and conditions of this
Agreement. 
 2.2    Independent Contractor. Sharp shall be deemed an independent contractor with respect to the
terms and provisions of this Agreement and shall not in any respect be deemed an agent or employee of Ascendis. All persons employed by Sharp in connection with the storage, labeling, packaging, assembly, and supply of the Products and/or the
Packaged Products, as applicable, to Ascendis shall be employees or agents of Sharp. Under no circumstances shall Sharp or any of its employees or agents be deemed to be employees or agents of Ascendis. 

 

	3.	 Governance. 

3.1    The Parties shall form a Joint Steering Committee (“JSC”) comprising of [***] ([***]) or [***] ([***])
members from each Party, including at least [***] ([***]) member of 

  
 3 

 
each Party’s senior management. The JSC shall meet [***] ([***]) times per [***] to discuss and evaluate the mutual collaboration and shall in good faith attempt to resolve any disputes in
connection with the Agreement. Each Party may call for an ad hoc teleconference as such Party deems necessary. As agreed between the Parties in each case, the meetings of the JSC may be carried out by teleconference, video conference or face-to-face, as the case may be, provided however that the Parties endeavor to meet face to face at least [***] per [***]. Decisions in the JSC must be unanimous. If this is
not possible, the dispute must be referred to Sharp and Ascendis executive management for negotiation. 
 3.2    Written
minutes of JSC meetings must be made alternately by each Party, or as agreed from time to time, and must be circulated for comments no later than [***] ([***]) [***] after each meeting. 

3.3    Sharp shall appoint an Account Manager and Ascendis shall appoint a primary logistics contact who shall both act as
single point of contact for the other Party in operational matters, except for quality related issues, which shall be governed in accordance with the Quality Agreement. The Sharp Account Manager and Ascendis’ primary logistics contact shall
engage vi teleconference at regular intervals to be mutually agreed. 
  

	4.	 Start-Up Activities. 

4.1    Start-Up Activities. As used in this Agreement, “Start-Up Activities” shall mean those activities that Ascendis and Sharp agree are necessary to commence packaging of the Products. Sharp shall complete the
Start-Up Activities in accordance with the project timeline agreed to in writing by the parties. Any protocols and reports prepared by Sharp in connection with the
Start-Up Activities shall be subject to Ascendis’ prior review and approval, which approval shall not be unreasonably withheld, conditioned or delayed. Sharp shall permit a representative of Ascendis to
observe and review the Start-Up Activities at the relevant Facilities during normal business hours and upon reasonable notice. The validation reports produced in connection with the Start-Up Activities shall be deemed Confidential Information of Sharp subject to Article 13 of this Agreement and shall be made available for Ascendis upon request. The costs associated with the Start-Up Activities shall be as agreed upon by the parties and shall be borne [***]. 

4.2    Purchase and Installation of Equipment, Molds and Tooling. Sharp shall be responsible for installing at its
Facilities any and all new equipment, molds and/or modifications to existing equipment and molds deemed necessary by Sharp for the packaging, assembly and labeling of the Products and for preparing the Packaged Products for shipment, and all costs
and expenses associated therewith; provided, however, that Ascendis shall be responsible for the costs and expenses associated with the development and manufacturing of the Tooling and any equipment other than Tooling purchased exclusively for use
under this Agreement (“Ascendis Specific Equipment”), as listed in Exhibit F. Sharp shall insure, maintain and store at its own cost the Tooling and Ascendis Specific Equipment at the Facilities while Ascendis shall retain all right, title
and interest in and to the Tooling and Ascendis Specific Equipment during and after the Term. Sharp shall not modify the Tooling or the Ascendis Specific Equipment without the consent of Ascendis, such consent not to be unreasonably withheld,
conditioned or delayed. Upon the expiration or termination of this Agreement, Sharp shall deliver all Tooling and Ascendis Specific Equipment to Ascendis. 

  
 4 

	5.	 Agreement to Supply; Forecasts; Purchase Orders. 

5.1    Generally. During the Term, Sharp shall store, package, assemble and label the Products and store and supply
to Ascendis the Packaged Products, all in accordance with the Specifications and the terms of this Agreement, and Ascendis shall pay for the Packaged Products in accordance with Article 5 of this Agreement. 

5.2    Forecasts and Purchase Orders. 

(a)    Beginning on the Effective Date and thereafter on or prior to the [***] preceding each [***] month of the Term,
Ascendis shall provide Sharp with a [***] ([***]) month rolling forecast (each, a “Forecast”) of Ascendis’ quantity and Delivery date requirements for the Packaged Products. 

(b)    The first [***] ([***]) months of each Forecast shall constitute a firm order (“Firm Order”) and shall be
binding upon Ascendis (whether or not Sharp receives a Purchase Order in connection with such [***] period). For the purposes of ordering packaging materials and scheduling capacity, Ascendis shall provide Sharp with purchase orders (each, a
“Purchase Order”) in connection with each such [***] ([***]) month Firm Order period for the Packaged Products to be supplied during that period. Every Purchase Order shall specify the quantities and Delivery dates for the Packaged
Products for the applicable Firm Order period. So long as the quantity and Delivery date requirements set forth in the Purchase Orders during any [***] ([***]) month Firm Order period are consistent with the applicable Firm Order, Sharp shall
respond with an order acknowledgment within [***] ([***]) business days. If the quantity and Delivery date requirements set forth in the Purchase Orders are not consistent with the applicable Firm Order, or in the event that Ascendis desires to
subsequently amend a Purchase Order, then the parties shall cooperate in good faith to issue and substitute a mutually agreeable revised Purchase Order (a “Revised Purchase Order”) at least [***] ([***]) days prior to the scheduled start
of the relevant production; provided, however that Sharp, prior to the agreement on a Revised Purchase Order, shall inform Ascendis of any Price implications as per section 6.1 (a) (i); and provided also that in the event a Revised Purchase Order is
not agreed upon by the parties, Ascendis shall be obligated to purchase all Packaged Products arising from the applicable Firm Order. 

(c)    Nothing printed or written on any Purchase Order, Sharp order acknowledgement or on any other similar form or
document shall modify or expand either party’s obligations under this Agreement, and any pre-printed terms and conditions contained in any such Purchase Order, order acknowledgement or other such form or
document shall not apply. 
 5.3    Production Requirements. Subject to the terms of this Agreement, Sharp shall
(a) devote the necessary production capacity to fulfill the quantity and Delivery date requirements set forth in each confirmed Purchase Order, and (b) [***] make available sufficient additional production capacity, subject to overtime charges
set forth in Exhibit A, to support all Forecasts; provided, that the parties shall cooperate in good faith to reach a mutually agreeable accommodation [***]. 

  
 5 

 5.4    Ascendis’ Supply Obligations. Sharp’s
obligations to fulfill any Purchase Order are subject to Ascendis’ obligation to provide Sharp with the following items within the following time periods: 

(a)    At least [***] ([***]) weeks prior to Sharp’s commencement of the production of the Packaged Products, any
text, graphics or other artwork to be printed by Sharp on the Packaging Materials, all of which shall be in conformity with all Applicable Laws; 

(b)    At least [***] ([***]) weeks prior to Sharp’s commencement of the production of the Packaged Products, any
Packaging Materials that are to be supplied by Ascendis; 
 (c)    At least [***] ([***]) weeks prior to Sharp’s
commencement of the production of the Packaged Products, the lot and expiry information for the Products; and 

(d)    At least [***] ([***]) weeks prior to Sharp’s commencement of the production of the Packaged Products, the
Products. 
 5.5    Storage Facilities; Inventory. Sharp shall store Products and Packaged Products at its
Facilities under conditions as specified in the Quality Agreement, and including such security measures as [***]. Sharp agrees to provide adequate storage space for the Products and the Packaged Products. Upon Ascendis’ request, and, if stored
for more than [***], subject to storage charges at the rates specified in Exhibit A, Sharp shall store Products for Ascendis until the Products expire, are consumed in production, or otherwise used. Sharp will maintain adequate inventories of
materials on hand or with suppliers to accommodate reasonable variations in packaging that may be required by Ascendis hereunder. Sharp shall store and deliver Packaged Product to Ascendis in accordance with the Specifications, and pursuant to the
terms and conditions set forth in this Agreement, including, but not limited to, Sections 5.2 and 5.4 hereof. Upon Ascendis’ request, Sharp shall store Packaged Products for Ascendis until the Products are shipped, expire or otherwise used, in
which case Sharp shall charge Ascendis for storage in accordance with its storage rates, as specified in Exhibit A. Sharp shall at the end of each [***] send Ascendis an inventory report of Products and Packaged Products held at the Facilities. 

5.6    Packaged Product Samples. Sharp shall provide Ascendis with representative lot samples of Packaged Products
promptly upon request. Such Packaged Product samples shall be shipped to Ascendis in accordance with the provisions set forth in Section 6.2. 

5.7    Serialization. Sharp shall provide to Ascendis the serialization services and maintenance parameters more
specifically set forth in Exhibit A-1, at the Price and subject to the additional terms and conditions provided for therein. 
  

	6.	 Price; Payment; Delivery. 

6.1    Determination of Prices. 

  
 6 

 (a)    The Price to be paid to Sharp by Ascendis for the supply of the
Packaged Products shall be as set forth on Exhibit A. The first review of pricing will occur [***] months prior to Ascendis’ expected launch date. Thereafter, the Parties will review the Price on an [***] basis. Sharp shall submit to Ascendis
revised pricing, reflecting (aa) [***], or (ab) [***], or (ac) [***]. Ascendis and Sharp shall execute an amended Exhibit A to this Agreement to reflect the adjustment to the Price. The foregoing notwithstanding, Sharp may adjust the Prices set
forth on Exhibit A at any time during the Term, in accordance with the following: 
  

	 	(i)	 Subject to prior information as per 5.2 (b), [***]; 

 

	 	(ii)	 In the event that [***], the parties agree [***]; and 

 

	 	(iii)	 In the event that [***], [***]. 

(b)    Prior to the commencement of any Subsequent Term, the parties shall negotiate in good faith the Price that shall
apply to such Subsequent Term. The parties shall take into account in any such negotiations [***], and, Sharp agrees that it shall not increase the cost of labor applicable to a Subsequent Term more than [***] per [***], and Sharp shall not increase
the cost of materials more frequently than [***] every [***]. . 
 (c)    The Prices set forth on Exhibit A do not
include sales, use, consumption, ad valorem, VAT or excise taxes of any taxing authority. The amount of such taxes, if any, will be added to the Price of the Packaged Products in effect at the time of shipment thereof and shall be reflected in the
invoices submitted to Ascendis by Sharp pursuant to Section 6.3. Ascendis shall pay the amount of such taxes to Sharp in accordance with the payment provisions relating to shipments of Packaged Products set forth in Section 6.3. 

6.2    Delivery. Sharp shall Deliver Packaged Product to Ascendis’ designee [***] (Incoterms 2010), at [***],
packed in accordance with the requirements set out in the Quality Agreement. Sharp shall arrange for the shipment of the Packaged Products with Ascendis Carriers. Ascendis shall pay outbound freight delivery costs as part of the price, according to
Exhibit A. Ascendis shall from time to time audit its approved carriers in accordance with Ascendis’ policies. As part of such audit(s), Ascendis agrees to [***]. In addition, Ascendis shall use only carriers who have agreed to comply with all
Applicable Laws and any other applicable federal, state and local laws and regulations. 
 6.3    Invoices. Sharp
shall submit invoices to Ascendis for all Deliveries of Packaged Products hereunder (i) upon Delivery of such Packaged Products to Ascendis’ designee, or (ii) upon placement, per Ascendis’ request, of released Packaged Products
into storage at the Facilities. Invoices shall be directed by Sharp personnel to Ascendis’ Accounts Payable Department ([***]@ascendispharma.com), or to such other persons, departments or locations as Ascendis may instruct in writing from time
to time. Invoices shall clearly state quantity, price and batch numbers, and shall reference the relevant Purchase Order. Each invoice shall be payable within [***] ([***]) days of the date of such invoice. 

  
 7 

 6.4    Risk of Loss. Title to all Products, Packaged Products,
all work in process to produce Packaged Products and/or any other property of Ascendis (“Ascendis Property”) shall at all times remain with Ascendis. Sharp shall not be liable for risk of loss to any Ascendis’ Property, except in the
case of negligence, gross negligence or willful misconduct by Sharp. The foregoing notwithstanding, Sharp’s [***] liability under this Agreement as it relates to Ascendis Property shall not exceed [***] Dollars ($[***]) in the case of
negligence, gross negligence or willful misconduct. 
 6.5    Non-Conforming
Packaged Products and Quantitative Defects. Ascendis shall have the right, within [***] ([***]) days following Sharp’s Delivery of Packaged Products to the Ascendis Carrier, to give Sharp written notice of rejection of the portion of such
shipment of Packaged Products that fails to meet the Specifications, or which otherwise breaches Sharp’s covenants and obligations under this Agreement. Sharp, at its sole cost and expense, shall provide Ascendis with any missing quantities
and/or replace as soon as [***] any packaging services for any non-conforming Packaged Products [***]. Any claim of a non-conforming shipment must be made in writing to
Sharp within the [***] ([***]) day period set forth above or it shall be deemed to have been waived by Ascendis. 

6.6    Target Yield Rate. Sharp and Ascendis agree to evaluate the amount of drug loss after Sharp performs the
services to produce [***]. After the completion of the [***], the Parties shall analyze the yield rate for those [***], and agree to a Target Yield Rate that will apply to the remaining Services, which will consider any samples or other related
issues that arise with the [***] runs. For lots manufactured after the first [***], Sharp shall reimburse Ascendis for drug loss stemming from a shortfall between the actual yield rate and the Target Yield Rate, subject to the general liability cap
pursuant to Section 6.4, calculated by using the [***] manufacturing cost of the Product, [***]. Ascendis and Sharp agree to on an annual basis mutually review whether the [***] is materially different from the [***] manufacturing cost and if
necessary to discuss in good faith any adjustments needed. 
  

	7.	 Quality Control; Access; Inspection; Samples. 

7.1    Quality Agreement. The parties have entered into a quality agreement with respect to the quality assurance
and packaging of Product by Sharp hereunder, which is referenced in Exhibit D (“Quality Agreement”). In the event there is any conflict relating to quality control procedures or cGMP-related activities between the terms and provisions of
this Agreement and the Quality Agreement, the applicable terms and provisions of the Quality Agreement shall control and prevail; provided that, with respect to all other matters, the terms, provisions and conditions of this Agreement shall control
and prevail. 
 7.2    Release. Sharp shall perform its own release of the Packaged Products. No later than [***]
days prior to the confirmed date of Delivery, Sharp shall forward such documentation as necessary for Ascendis to perform final release (the “Release Documentation”) to Ascendis. The requirements for Release Documentation shall be
specified in the Quality Agreement. Final Release shall be performed by Ascendis’ Qualified Person, such Final Release not to be unreasonably withheld. Delivery is subject to Final Release except in the event that Ascendis requests for shipment
in Quarantine (as defined in the Quality Agreement). 

  
 8 

 7.2    Modification of Specifications. The Specifications may not
be modified or changed without the mutual written agreement of the parties. 
 7.3    Storage Requirements. Sharp
shall use the Products and the Packaging Material on a first in, first out basis, unless otherwise instructed by Ascendis in writing, and shall not use either the Products or the Packaging Material beyond the shelf life required under any Applicable
Law. 
 7.4    Notices Regarding Packaging Materials. Sharp shall promptly contact Ascendis, care of
Ascendis’ Quality Assurance Department (or such other persons or departments as Ascendis may instruct), in the event that Sharp anticipates making changes to any Packaging Material or in the event Sharp considers any current Packaging Material
to be nonconforming with the Specifications or Applicable Law. 
 7.5    Quality Inspections. Sharp shall perform
certain in-coming, in-process and finished product inspections necessary to assure the quality of the Packaging Material and Packaged Products as provided for in
Sharp’s standard procedures and any inspections required by Applicable Law of the United States or as otherwise required by the Specifications. For purposes of this Agreement, inspections performed [***] shall be considered routine and shall be
performed at Sharp’s expense. [***] will be completed at cost and at Ascendis’ expense. All inspections and related results shall be performed, documented and summarized by Sharp in accordance with Sharp’s standard procedures, the
Specifications and Applicable Law of the United States. The parties hereto will negotiate in good faith any unanticipated burdens resulting from changes made to any Applicable Law after the Effective Date. 

7.6    Records. For the period set forth in Section 7.10, Sharp shall maintain detailed records on Packaging
Material usage and Packaged Product production, including lot numbers, serial numbers, and shipping information relating to the Packaged Products, so that the Packaged Products can be traced in case of a recall. Sharp’s Packaged Product records
shall be sufficient such that Sharp shall be capable of responding to Packaged Product inquiries by Ascendis within [***] ([***]) hours following notification, including providing the lot numbers and the location within the Facilities of the
Packaged Products in question. 
 7.7    Recalls. Ascendis shall have sole responsibility for initiating
and managing any recall or withdrawal of the Packaged Products, and shall bear all costs and expenses relating thereto. Upon receiving from any Regulatory Authority having jurisdiction any direction to withdraw or recall any Packaged Product from
the market, the receiving party shall promptly notify the other party. [***] Sharp shall provide such assistance as Ascendis may reasonably request in connection with any such withdrawal or recall. Ascendis shall provide copies of Field Alerts
(initial and final), Recalls, Medical Assessments and/or follow-up reports to Sharp within [***] ([***]) [***] days. Sharp shall have no liability with respect to any recall or withdrawal of Packaged Products
except to the extent arising directly from Sharp’s negligence, gross negligence or willful misconduct, in which case Sharp’s liability shall be limited to [***] Dollars ($[***]) per recall. 

7.8    Maintenance of Facilities. In the event Sharp fails or anticipates it will fail to maintain the Facilities
in accordance with the Specifications and all Applicable Laws of the 

  
 9 

 
United States, or in the event Sharp receives any notice from any Regulatory Authority of the United States with respect to its maintenance of the Facilities, and only if such maintenance or
notice affects the Products, Sharp shall promptly notify Ascendis, care of Ascendis’ Quality Assurance Department (or such other persons or departments as Ascendis may instruct), provide copies of such notice to Ascendis and, if such Regulatory
Authority notice relates specifically to the Packaged Products, provide a copy of Sharp’s response to such Regulatory Authority. 

7.9    Inspections and Audits. Ascendis and all Regulatory Authorities shall have access at reasonable times and
with reasonable frequency to Sharp’s Facilities where Products are located for the purpose of conducting inspections of, performing quality control audits with respect to, or witnessing, the processing, storage or transportation of Products,
Packaged Products or Packaging Materials, and Ascendis shall have access at reasonable times and with reasonable frequency to the results of any inspections relating to the Products that are performed by Sharp or at Sharp’s direction. Sharp
shall use its reasonable efforts to cause Sharp’s suppliers or agents to permit Ascendis similar access to their respective facilities, data and records. Such inspections, audits and visits shall be conducted by Ascendis’ personnel upon
reasonable notice and during normal business hours. Sharp shall be entitled to charge a fee for hosting Regulatory Authority audits from [***], unless such audits are “for cause” due to quality issues. 

7.10    Retention of Samples and Records. Sharp shall retain and, upon request by Ascendis at reasonable times and
with reasonable frequency, make available to Ascendis, (a) copies of the quality control records maintained in accordance with Section 7.6 and otherwise in relation to the Packaged Products, (b) copies of inspection results of all the
inspections performed in relation to the Packaged Products, (c) records of each batch of Packaged Product and (d) samples of the Packaging Materials and Packaged Product, upon reasonable request. All quality control and assurance records
and samples will be maintained by Sharp for [***] ([***]) year following the Packaged Product expiration date or such longer time period as may be required by Applicable Law of the United States. 

7.11    Government Inspections, Seizures and Recalls. If any Regulatory Authority makes an inspection at
Sharp’s Facilities, seizes Products or Packaged Products or requests a recall of Packaged Products, Sharp shall promptly notify Ascendis’ Quality Assurance Department (or such other persons or departments as Ascendis may instruct), and
Sharp shall take such actions as may be required under the Specifications or as may be reasonably requested in writing by Ascendis; [***]. Sharp shall promptly send duplicate reports relating to such inspections to Ascendis care of Ascendis’
Quality Assurance Department (or such other persons or departments as Ascendis may instruct). 
 7.12    Legal and
Regulatory Filings and Requests. Sharp and Ascendis shall cooperate and be diligent in responding to all requests for information from, and in making all required filings, [***], with any Regulatory Authority having jurisdiction to make such
requests or require such filings. Sharp shall, [***], obtain and comply with all licenses, consents, permits and regulations which may from time to time be required by an appropriate Regulatory Authority of the United States with respect to the
performance of its obligations hereunder. 

  
 10 

 7.13    Complaints. In connection with any Packaged Product
complaints reasonably relating to packaging services that are forwarded by Ascendis to Sharp, Sharp shall conduct a [***] investigation of such complaint, at no additional cost to Ascendis. 

 

	8.	 Warranties; Limitation of Liability. 

8.1    General Warranties. Sharp warrants that: (a) the Products shall be stored, processed, packaged and
labeled in accordance with the Specifications and all Applicable Laws of the United States; (b) the Packaged Products furnished by Sharp to Ascendis under this Agreement (i) shall be at the time of Delivery to a Ascendis Carrier of the
quality specified in, and shall conform with, the Specifications for packaging and any Applicable Law of the United States, (ii) shall be stored and supplied in conformity with the Specifications and any Applicable Law of the United States and
(iii) shall not contain any material provided by or on behalf of Sharp, which material has not been used or stored in accordance with the Specifications and any Applicable Law of the United States; (c) it will not introduce any materials
not provided for in the Specifications that would cause the Packaged Products to be adulterated within the meaning of Section 501 of the FDCA; and (d) the Packaged Products shall not be misbranded by Sharp within the meaning of the FDCA
([***]). Any claim by Ascendis for breach of warranty that is not brought before the expiry of the applicable Packaged Product shall be deemed to have been waived by Ascendis. 

8.2    Disclaimer; Limitation of Liability. NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT TO THE CONTRARY THE
WARRANTIES WITH RESPECT TO THE STORING, PACKAGING, ASSEMBLY, LABELING AND DELIVERY OF THE PRODUCTS AND THE PACKAGED PRODUCTS STATED IN THIS ARTICLE 8 ARE IN LIEU OF ALL OTHER WARRANTIES OF SHARP, ORAL OR WRITTEN, EXPRESSED OR IMPLIED, INCLUDING
IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. EXCEPT AS OTHERWISE SPECIFICALLY PROVIDED FOR HEREIN, IN NO EVENT SHALL [***] AGGREGATE LIABILITY EXCEED [***] DOLLARS ($[***]) [***] HAVE ANY LIABILITY FOR ANY EXEMPLARY,
PUNITIVE, INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES, WHETHER BASED ON CONTRACT, TORT, STRICT LIABILITY OR ANY OTHER THEORY OR FORM OF ACTION [***]. [***]. 
  

	9.	 Intellectual Property Rights. 

9.1    Intellectual Property Rights of Ascendis; Grant of License. Except as specifically set forth in
Section 9.2, [***]. Ascendis hereby grants to Sharp a [***] as may be necessary for Sharp’s fulfillment of its services in accordance with this Agreement (including in accordance with the Specifications) [***]. Except as set forth in the
immediately preceding sentence, Sharp shall have no other rights to use the Brand Image. 
 9.2    Ownership of Other
Property. All right, title and interest in and to (a) [***], (b) [***], and (c) [***]. Nothing in this Agreement shall be construed to grant to Ascendis any right to any trademark, trade name, copyright, patent or other proprietary technology or
know-how owned by Sharp. 

  
 11 

	10.	 Indemnification. 

10.1    Sharp’s Indemnification of Ascendis. Sharp shall defend, indemnify and hold Ascendis and its officers,
directors and employees (each, a “Ascendis Indemnified Party”) harmless from and against any and all losses, liabilities, damages, claims for damages, suits, recoveries, judgments or executions resulting from a third party claim (including
reasonable attorneys’ fees and expenses) (collectively, “Damages”) that may be incurred by any Ascendis Indemnified Party arising out of or on account of: (a) [***]; or (b) [***]. 

10.2    Ascendis’ Indemnification of Sharp. Ascendis shall defend, indemnify and hold Sharp and its Affiliates
and the officers, directors and employees thereof (each, a “Sharp Indemnified Party”) harmless from and against any and all Damages that may be incurred by any Sharp Indemnified Party arising out of or on account of: (a) [***]; (b) [***];
(c) [***]; (d) [***]; or (e) [***]. 
 10.3    Indemnification Procedure. Any party seeking indemnification in
accordance with this Article 10 (the “Indemnified Party”) shall notify in writing the other party from whom such indemnification is sought (the “Indemnifying Party”) of any third party claim made against the Indemnified Party,
specifying the basis given by such third party of such claim. The Indemnified Party shall thereupon give the Indemnifying Party reasonable access to the books, records and assets of the Indemnified Party which evidence, support or directly relate to
such claim. The Indemnifying Party shall have the right, upon giving written notice to the Indemnified Party within [***] ([***]) [***] days after the receipt of any such notice of claim, to undertake the defense of or, with the consent of the
Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed), to settle or compromise such claim. The failure of the Indemnifying Party to give such notice and to undertake the defense of or to settle or compromise
such a claim shall constitute a waiver of the Indemnifying Party’s rights under this Section 10.3 [***]; provided however, that the Indemnified Party shall not settle or compromise such claim without the prior written approval of the
Indemnifying Party (which approval shall not be unreasonably withheld, conditioned or delayed). The election by the Indemnifying Party, pursuant to this Section 10.3 to undertake the defense of a third-party claim shall not preclude the party
against which such claim has been made also from participating or continuing to participate in such defense, so long as such party bears its own legal fees and expenses for so doing. 

10.4    Survival. The indemnification obligations set forth in this Article 10 shall survive the expiration or
termination of this Agreement. 
  

	11.	 Insurance. 

Sharp shall acquire and maintain at its sole cost and expense: (a) Statutory Worker’s Compensation Insurance and Employer’s
Liability Insurance; (b) risk coverage of not less than [***] dollars ($[***]) for physical loss or damage to materials including Products and Packaged Products while at the Facilities or under its control; and (c) products liability,
bodily injury and property damage insurance with a combined single limit of not less than [***] dollars ($[***]). 

  
 12 

	12.	 Term; Termination. 

12.1    Initial Term; Term. The initial term of this Agreement shall begin on the Effective Date and shall terminate
on December 31, 2025 (the “Initial Term”). This Agreement will be automatically extended for additional two-year periods (such additional periods are each a “Subsequent Term,” and
collectively with the Initial Term, the “Term”). The Term shall end upon the expiration of this Agreement or its earlier termination as set forth in Section 12.2. 

12.2    Termination. This Agreement may be terminated upon the occurrence of any of the following: 

(a)    The parties may terminate this Agreement by mutual written consent at any time; 

(b)    Either party may terminate this Agreement by giving thirty (30) days written notice to the other party in the
event the other party has breached any representation, warranty or obligation contained in this Agreement and/or has defaulted in the performance of any of its duties or obligations hereunder in any material respect and such breach or default has
not been remedied within thirty (30) days after written notice of the breach or default has been received; 

(c)    Either party may terminate this Agreement if a voluntary petition in bankruptcy should be filed by the other party
under the United States Bankruptcy Code, if an involuntary petition under the United States Bankruptcy Code should be filed against the other party, or if a receiver should be appointed for the other party or its property; 

(d)    Either party may terminate this Agreement pursuant to Section 14.2. 

(e)    Ascendis may terminate this Agreement without cause by giving one (1) year’s notice to Sharp. Sharp may
terminate this Agreement without cause by giving two (2) years’ notice to Ascendis. In both cases however, such termination can take effect no earlier than by the expiry of the Initial Term. 

12.3    Effect of Expiration or Termination. 

(a)    The expiration or termination of this Agreement shall not release either party from any of its obligations accrued
prior to the effective date of termination, and each party shall remain responsible for the performance of its respective obligations and agreements which are expressly stated to be obligations which survive the termination of this Agreement.
Furthermore, the rights to terminate provided for hereinabove are in addition to any other right, remedy, or election either party may have hereunder or at law or in equity. 

(b)    Within [***] ([***]) days of the effective date of the expiration or termination of this Agreement for any reason,
Ascendis shall purchase any Packaging Materials that Sharp has purchased exclusively for Ascendis in accordance with this Agreement for the production of the Packaged Products. 

(c)    Upon the effective date of expiration or termination of this Agreement, Sharp shall immediately deliver to Ascendis
or its designee all Products, and all text, graphics and other artwork and Packaging Materials purchased or provided by Ascendis. Sharp shall also deliver to Ascendis or its designee all Packaged Products produced hereunder, and shall invoice
Ascendis therefor in accordance with the terms of Section 6.3. 

  
 13 

 (d)    Upon termination or expiration of this Agreement and upon the
written request of Ascendis, Ascendis and Sharp will enter into a tech transfer agreement (“TTA”), under which Sharp provides necessary support and assistance enabling Ascendis to obtain continued supply of Packaged Product from an
alternate supplier. The costs and expenses of such tech transfer shall be agreed upon in such TTA [***]. 
  

	13.	 Confidentiality. 

(a)    Confidentiality.    Sharp and Ascendis agree to keep secret and confidential any and all
proprietary and non-public information of the other party (“Confidential Information”) disclosed by the other party hereunder or through any prior disclosure and not to disclose such Confidential
Information to any person or entity, except: (i) to Affiliates; provided that such Affiliates are made aware of the confidential nature of the Confidential Information and agree to comply with the terms of this Agreement; (ii) to employees
and authorized representatives of each party having a need to know the information in order to fulfill such party’s obligations hereunder; or (iii) as required by an applicable Regulatory Authority. The parties shall use the Confidential
Information solely for the purpose of carrying out the obligations contained in the Agreement. The obligations imposed by this Section shall not apply to any Confidential Information: 

 

	 	(i)	 that, at the time of disclosure, is in the public domain; 

 

	 	(ii)	 that, after disclosure, becomes part of the public domain by publication or otherwise, through no fault of the
recipient; 

  

	 	(iii)	 that, at the time of disclosure, is already in the recipient’s possession, except through prior disclosure
by the disclosing party, and such possession can be properly documented by the recipient in its written records, and was not made available to the recipient by any person or party owing an obligation of confidentiality to the disclosing party;

  

	 	(iv)	 that is rightfully made available to the recipient from sources independent of the disclosing party;

  

	 	(v)	 that is required to be disclosed in the course of litigation or other legal or administrative proceedings;
provided that in all such cases the party receiving the Confidential Information shall, to the extent permitted, give the other party prompt notice of the pending disclosure and shall cooperate in such other party’s attempts, at such other
party’s sole expense, to seek an order maintaining the confidentiality of the Confidential Information; or 

  

	 	(vi)	 that is required to be disclosed by Applicable Laws; provided that in all such cases the party receiving the
Confidential Information shall, to the extent permitted, give the other party prompt notice of the pending disclosure and shall cooperate in such other party’s attempts, at such other party’s sole expense, to seek an order maintaining the
confidentiality of the Confidential Information. 

  
 14 

 (b)    Survival.    The obligation of
confidentiality and nonuse set forth in this Article 13 shall survive for a period of [***] ([***]) years beyond the termination or expiration of this Agreement. 

(c)    Ownership of Confidential Information.    Confidential Information shall remain the
exclusive property of the disclosing party. In no event shall any of either party’s Confidential Information, technology, know-how, intellectual property (or rights thereto) become the property of the
other party. 
 (d)    [***] Consent.    [***] shall not release to any third party any non-public information with respect to the terms of this Agreement without the prior written consent of [***]. 

(e)    If a party concludes that a copy of this Agreement must be filed with the United States Securities Exchange
Commission or other regulatory agency (“SEC”) (or equivalent foreign agency or a securities exchange), such party will use [***] to provide the other party with a copy of this Agreement showing any provisions hereof as to which the party
proposes to request confidential treatment, and to provide the other party with an opportunity to comment on any such proposed redactions and to suggest additional redactions. The filing party will take such other party’s [***] comments into
consideration before filing the Agreement. 
  

	14.	 Miscellaneous. 

14.1    Authority to Enter Into Agreement. Each party represents and warrants that it is authorized to enter into
this Agreement and that in so doing it is not in violation of the terms and conditions of any contract or other agreement to which it may be a party. 

14.2    Force Majeure. Performance under this Agreement (other than performance of payment obligations) shall be
excused to the extent prevented or delayed by any event or circumstance, which is beyond the reasonable control of the party whose performance is to be excused hereunder, including but not limited to fire, flood, explosion, widespread product
tampering by third parties, governmental acts or regulations, war, labor difficulties, shortages or unavailability of materials, or any act of God. The party affected shall promptly notify in writing the
non-affected party of the event of force majeure and the probable duration of the delay. Any delay caused by an event of force majeure happening within the Initial Term shall toll the Initial Term, which shall
be extended by the length thereof. In the event a force majeure prevents performance by one party for more than [***] ([***]) months, either party may terminate this Agreement. 

14.3     Public Announcements. The parties agree to determine jointly the contents of any public announcement
informing the public about the existence of this Agreement between the parties and, except as may be required by law or the rules of any national securities exchange, neither party shall issue or cause the issuance of any such public announcement
without the express prior approval of an executive officer of each party. 

  
 15 

 14.4    Amendments. Except to the extent otherwise provided in
Section 6.1 of this Agreement with respect to amendments to Exhibit A, this Agreement may not be modified, amended or altered except pursuant to a written instrument signed by both parties. 

14.5    Governing Law. This Agreement is made subject to the laws of the State of Delaware, without reference to
principles of conflicts of laws. Each party agrees that suit may be instituted at any federal court in the Eastern District of Pennsylvania or in state court in Lehigh County in the Commonwealth of Pennsylvania and each waives any objection which
such party may now or hereafter have to the laying of the venue of any such action, suit or proceeding, and irrevocably submits to the jurisdiction of any such court. Any and all service of process and any other notice in any such action, suit or
proceeding shall be effective against a party if given as provided in Section 14.7. Nothing contained herein shall prevent or delay either party from seeking, in any court of competent jurisdiction in Pennsylvania, specific performance or other
equitable remedies in the event of any breach or intended breach by the other party of any of its obligations hereunder. 

14.6    Assignment. Neither party may, without the prior written consent of the other party, delegate, transfer,
convey, assign or pledge any of its rights or obligations under this Agreement to any other person, firm or corporation; provided however, that such consent shall not be unreasonably withheld and provided further that neither party need to obtain
any consent in the event a party assigns this Agreement to an entity that succeeds to all or substantially all of such party’s business or assets. Additionally, Ascendis is free to assign its rights and obligations, including (without
limitation) to a third party acquiring, by purchase or license, rights to further develop or commercialize Product. 

14.7    Notice. Any and all notices permitted or required to be given hereunder will be deemed duly given:
(a) upon actual delivery, if delivery is by hand; (b) [***] ([***]) [***] days after delivery into the United States Postal Service mail, if delivery is by postage paid registered or certified return receipt request mail; (c) [***] ([***])
[***] day after delivery to a nationally recognized overnight carrier, if delivery is made by [***] carrier guaranteeing [***] day delivery; or (d) upon receipt of evidence of successful transmission, if delivery is by facsimile. Each such
notice shall be sent to the respective party at the address or facsimile number indicated below or at any other address as the respective party may designate by notice delivered pursuant hereto. 

If to Ascendis: 
 Ascendis
Pharma A/S 
 Tuborg Boulevard 12, 2900 Hellerup, Denmark 

Attention: General Counsel 
 If
to Sharp: 
 SHARP CORPORATION 

7451 Keebler Way 
 Allentown,
Pennsylvania 18106 
 Attention: CFO 

Telecopier Number: (610) 254-1765 

  
 16 

 14.8    Compliance with Laws. In the performance of this
Agreement, both parties agree to comply with all applicable federal, state or local laws, statutes, rules, regulations and ordinances, including any Applicable Laws, subject to any specific limitations set forth herein. 

14.9    Entire Agreement. This Agreement, including all Exhibits attached hereto and made a part hereof, contains
the entire understanding of the parties, superseding in all respects any and all prior oral or written agreements or understandings pertaining to the subject matter hereof, and except as otherwise specifically provided for herein, shall be amended
or modified only by written agreement executed by the parties hereto. Delivery by reliable electronic means, including facsimile or email, shall be an effective method of delivering the executed Agreement. This Agreement may be stored by electronic
means and either an original or an electronically stored copy of this Agreement can be used for all purposes, including in any proceeding to enforce the rights and/or obligations of the parties to this Agreement. 

14.10    Severability. If and to the extent that any court of competent jurisdiction holds any provision or part of
this Agreement to be invalid or unenforceable, such holding shall in no way affect the validity of the remainder of this Agreement. 

14.11    Waiver. A waiver by either party of any of the terms and conditions of this Agreement in any instance
shall not be deemed or construed to be a waiver of such term or condition for the future. 
 14.12    Headings.
Headings in this Agreement are included for ease of reference only and have no legal effect. 

14.13    Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original and all of which together shall constitute one and the same instrument. 
 14.14    Drafting. This
Agreement was negotiated at arm’s-length and entered into freely by the parties and upon the advice of their respective counsel. All parties hereto are to be deemed the drafters of this Agreement. No
provision hereof shall be construed in favor of or against any party hereto based upon principles of contra proferentem or any other presumption as to inequality of bargaining power or otherwise. 

[Remainder of page intentionally left blank] 

  
 17 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed in their
respective names and on their behalf, as of the date first above written. 
  

									
	ASCENDIS	 		 	SHARP CORPORATION
					
	By:	 	 /s/ Jan Møller Mikkelsen
	 		 	By:	 	 /s/ Jeff Benedict

					
	Title:	 	CEO	 		 	Title:	 	Chief Commercial Officer
					
	Date:	 	06-Feb-2020	 		 	Date:	 	Feb 5 2020
		 		 		 		 	
					
	By:	 	 /s/ Michael Wolff Jensen
	 		 		 	
					
	Title:	 	Chief Legal Officer	 		 		 	
					
		 	06-Feb-2020	 		 		 	

  
 18 

 EXHIBIT A 

PRODUCTS / PRICES 

[***] 
 Ascendis agrees to an annual revenue
minimum of $[***] for packaged kits [***] 

  
 19 

 EXHIBIT A-1 

SERIALIZATION PRICES AND 

TERMS AND CONDITIONS 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

  
 20 

 EXHIBIT B 

SPECIFICATIONS 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

  
 21 

 EXHIBIT C 

INITIAL FORECAST 
 Omitted
pursuant to Regulation S-K, Item 601(a)(5) 

  
 22 

 EXHIBIT D 

QUALITY AGREEMENT 
 Omitted
pursuant to Regulation S-K, Item 601(a)(5) 

  
 23 

 EXHIBIT E 

TERRITORY 
 Omitted pursuant
to Regulation S-K, Item 601(a)(5) 

  
 24 

 EXHIBIT F 

ASCENDIS SPECIFIC EQUIPMENT 

Omitted pursuant to Regulation S-K, Item 601(a)(5) 

  
 25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]